
References

References

1. Abildgaard, U., "Purification of Two Progressive Antithrombins of Human Plasma," *Scand. J. Clin. Lab Invest.* 19:190-195, 1967.
2. Abramowitz, K., "Economics of Automation," *Plasma Quarterly* 1(2):41,61-62, 1979.
3. Acker, Loren, Engineering and Research Associates, Inc., Tucson, AZ, personal communication, Feb. 23, 1984.
4. Adams, D. M., Joyce, G., Richardson, V. J., et al., "Liposome Toxicity in the Mouse Central Nervous System," *J. Neurol. Sci.* 31:173-180, 1977.
5. Aledort, L. M., "AIDS: An Update," *Hospital Practice* 18(9):159-171, 1982.
6. Aledort, L. M., "Lessons From Hemophilia," *N. Engl. J. Med.* 306:607-608, 1982.
7. Aledort, L. M., Pannekoek, H., Vehar, G. A., and Veltkamp, J. J., "What Is the Prospective Impact of Recombinant DNA Technique on the Production of Human Plasma Derivatives? Which Are the Derivatives Where Donor Plasma Could Be Replaced?" *Vox Sang.* 44:390-395, 1983.
8. Alexander, M. R., Ambre, J. J., Liskow, B. I., and Trost, D. C. "Therapeutic Use of Albumin," *J. A.M.A.*, 241:2527-2529, 1979.
9. Almog, J., Baldwin, J. E., and Huff, J., "Reversible Oxygenation and Antioxidation of a "Capped" Porphyrin Iron (II) Complex," *J. Am. Chem. Soc.* 97:227-228, 1975.
10. Amberson, W. R., Jennings, J. J., and Rhode, C. N., "Clinical Experience With Hemoglobin-Saline Solutions," *J. Appl. Physiol.* 1:469-489, 1949.
11. Ambler, R. P., and Scott, G. K., "The Partial Amino Acid Sequence of the Penicillinase Coded by *E. coli* Plasmid pR6K," *Proc. Natl. Acad. Sci.* 75:3732-3936, 1978.
12. American Association of Blood Banks, "AABB Members Comment on the Medicare Prospective Payment System," American Association of Blood Banks, Arlington, VA, no date.
13. American Association of Blood Banks, press release on ACT representation, Arlington, VA, January 1984.
14. American Association of Blood Banks, American Red Cross and Council of Community Blood Centers, "Joint Statement on Acquired Immune Deficiency Syndrome (AIDS) Related to Transfusion" (Jan. 13, 1983), *Transfusion* 23(2):87-88, March-April 1983.
15. *American Association of Blood Banks Clearinghouse Transaction Reports* (Arlington, VA: American Association of Blood Banks, 1973-83).
16. American Association of Blood Banks, *Blood Clearinghouse Lifeline Information Sheet* (Arlington, VA: American Association of Blood Banks, May 1984).
17. American Association of Blood Banks, *Blood Transfusion Therapy: A Physician's Handbook* (Arlington, VA: American Association of Blood Banks, 1983).
18. American Association of Blood Banks, *Guide for the National Clearinghouse Lifeline Program of the American Association of Blood Banks, Third Edition* (Arlington, VA: American Association of Blood Banks, July 1984).
19. American Association of Blood Banks, Hospital Transfusion Committee Meeting, Arlington, VA, Apr. 20, 1984.
20. American Association of Blood Banks, *Interim Annual Report: 1982-1983* (Arlington, VA: American Association of Blood Banks, 1983).
21. *American Association of Blood Banks Newsletter* (Arlington, VA: American Association of Blood Banks, January 1984).
22. American Association of Blood Banks, "Plasma Products: Use and Management" (Arlington, VA: American Association of Blood Banks, 1982).
23. American Association of Blood Banks, "Plasma Products: Use and Management," Educational program at Annual Meeting of the American Association of Blood Banks, New York, NY, 1983.
24. American Association of Blood Banks, Seminar on Prospective Payment at Annual Meeting of the American Association of Blood Banks, New York, NY, 1983.
25. *American Association of Blood Banks Newsbriefs*, "AABB AIDS Survey Completed" 7(4): 1-2, April, 1984.
26. *American Association of Blood Banks Newsbriefs*, "AABB Announces New Physician Self-Assessment Program" 7(4):12, April, 1984.
27. *American Association of Blood Banks Newsbriefs*, "AABB Takes Stand on Organ Procurement and Transplantation" 7(4):1,8, April 1984.
28. American Association of Blood Banks, *Untitled* [Information Sheet] (Arlington, VA: American Association of Blood Banks, 1982).
29. American Association of Blood Banks, *Untitled*

- [1981 American Association of Blood Banks, American Red Cross, and Council of Community Blood Banks Blood Data], 1983.
30. American Blood Commission Annual Meeting, Washington, DC, Dec. 13, 1983.
 - 31a. American Blood Commission, *Blood Facts: Answers to Some Often Asked Questions* (Arlington, VA: September, 1981).
 - 31b. American Blood Commission Board of Directors Meeting, *Report by Regionalization Committee* (Washington, DC: March, 1983).
 32. American Blood Commission, *Final Report: Regional Association of Blood Service Units Program, Contract NO1-HB-6-2967 SA #2: Operating Relationship and Resource Sharing (of Blood Banking Services) on a Regional Basis* (Washington, DC: Jan. 31, 1980).
 33. American Blood Commission, *Financial Statements as of March 31, 1983* (Arlington, VA: 1983).
 34. American Blood Commission, *Regionalization Program Information Sheet* (Washington, DC: September, 1983).
 35. American Blood Commission, *Summary Report of the Task Force on Donor Recruitment* (Arlington, VA: American Blood Commission, 1977).
 36. *American College of Surgeons 69th Annual Clinical Congress October 16-21, 1983, Post-graduate Course 1: Pre- and Post-Operative Care: Blood and How to Use It*, G. S. Moss, Chair, American College of Surgeons, Chicago, IL, 1983.
 37. American Medical Association, Council on Scientific Affairs: Organ Donor Recruitment *J. A.M.A.* 246:2157, 1981.
 38. American Medical Association House of Delegates, "AIDS and Blood Donations," Resolution 39 (A-84), Chicago, IL, June 20, 1984.
 39. American Medical Association, *General Principles of Blood Transfusion* (Monroe, WI: American Medical Association, 1977).
 40. American Red Cross, *Annual Report 1980* (Washington, DC: 1980).
 41. American Red Cross, *Annual Report 1981* (Washington, DC: 1981).
 42. American Red Cross, *Annual Report 1982*, (Washington DC: 1982).
 43. American Red Cross, *Annual Report 1983* (Washington, DC: 1983).
 44. American Red Cross, *Blood Services Directive 1.57* (Washington, DC: American Red Cross, Revised, 1982).
 45. American Red Cross, *Blood Services Operations Report: 1979-1980*, ARC 591 (Washington, DC: 1980).
 46. American Red Cross, *Blood Services Operations Report: 1980-1981*, ARC 591 (Washington, DC: 1981).
 47. American Red Cross, *Blood Services Operations Report: 1981-1982*, ARC 591 (Washington, DC: 1982).
 48. American Red Cross, *Blood Services Operations Report: 1982-1983*, ARC 591 (Washington, DC, 1983).
 49. American Red Cross, *Red Cross Blood Donor Inquiry*, Blood Services, Mid-American Region, Survey conducted by J. Walter Thompson Co., Chicago, IL, 1978.
 50. American Red Cross, *Report 1982: Blood Research and Development*, ARC 2729, Washington, DC, October 1982.
 51. American Red Cross, "Summary-Blood Service Regions" (activities related to organ and tissue services), attachment N, Mar. 8, 1984.
 52. Aroesty, J., and Rettig, R. A., *The Cost Effects of Improved Kidney Transplantation* (Santa Monica, CA: The Rand Corp., 1984).
 53. Aronson, D. L., Director, Coagulation Branch, Division of Blood and Blood Products, Center for Drugs and Biologics, U.S. Food and Drug Administration, personal communication, June 1984.
 54. Aronstam, A., Arblaster, P. G., Rainsford, S. G., et al., "Prophylaxis in Hemophilia: A Double-Blind Controlled Trial," *Brit. J. Haemat.* 33:81-90, 1976.
 55. Aster, R., "Clinical Use of Platelet Concentrates," *Transfusion and Immunology: Plenary Session Lectures of the XIV Congress of the International Society of Blood Transfusion and the X Congress of the World Federation of Hemophilia*, E. Ikkala and A. Nykanen (eds.) 1975.
 56. Baker, S. B., and Dawes, R. L. F., "Experimental Hemoglobinuric Nephrosis," *J. Pathol. Bacteriol.* 87:49-56, 1964.
 57. Baldassare, J. J., Knipp, M. A., and Kahn, R. A., "Reconstitution of Platelet Proteins Into Phospholipid Vesicles: Functional Proteoliposomes," unpublished.
 58. Baldwin, J. E., and Huff, J., "Binding of Dioxigen to Iron (II). Reversible Behaviour in Solution," *J. Am. Chem. Soc.* 95:5757-5759, 1973.
 59. Baldwin, J. E., "Recent Researches Towards Oxygen Carrying Chelates as Blood Substitutes,"

- Advances in Blood Substitute Research**, R. B. Bolin, G. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983), pp. 149-156.
60. Baltimore, D., "Viral RNA-Dependent DNA Polymerase," *Nature* 226:1209-1211, 1970.
 61. Barker, L., and Hoofnagle, J., "Transmission of Viral Hepatitis, Type B, By Plasma Derivatives," *Develop. Biol. Standard*, 27:178, 1974.
 62. Barker, L., "World Blood Resources: The Relationship of Medical Needs for Whole Blood, Red Cells, and Plasma Derivatives to Blood Collection, **Plasmapheresis** and Fractionation Practices," Report for the World Blood Resources Subcommittee of the Council of the International Society of Blood Transfusion, Montreal, Canada, August 1980.
 63. Barrow, E. S., Reisner, H. M., and Graham, J. B., "The Separation of **Willebrand** Factor From Factor VIII-Related Antigen," *Brit. J. Haematol.* 42:455-468, 1979.
 64. Bart, K. J., Macon, E. J., Whittier, F. C., et al., "Cadaveric Kidneys for Transplantation" *Transplantation* 31:379, 1981.
 65. Baxter-Travenol Laboratories, Inc., "Annual Report and Form 10-K for Fiscal Year Ended December 31, 1982," Securities and Exchange Commission, Commission File No. 1-4448.
 66. Bayer, R., "Gays and the Stigma of 'Bad Blood'," *Hastings Center Report* 13(2):5-7, April 1983.
 67. Benesch, R., and Benesch, R. E., "The Effect of Organic Phosphates From the Human Erythrocyte on the Allosteric Properties of Hemoglobin," *Biochem. Biophys. Res. Comm.* 26: 162-167, 1967.
 68. Benesch, R. E., Yung, S., Suzuki, T., et al., "Pyridoxal Compounds as Specific Reagents for the Alpha and Beta N-termini of Hemoglobin," *Proc. Natl. Acad. Sci.* 70:2595-2599, 1973.
 69. Benesch, R. E., Benesch, R., Renthall, R. D., et al., "Affinity Labeling of the Polyphosphate Binding Site of Hemoglobin," *Biochemistry* 64:3576-3581, 1972.
 70. Bennett, J. S., and Vilaire, G., "Exposure of Platelet Fibrinogen Receptors by ADP and Epinephrine," *J. Clin. Invest.* 64:1393-1401, 1979.
 71. Bettinghaus, E. P., and Milkowich, M. B., "Donors and Non-Donors: Communication and Information," *Transfusion* 15:165-180, 1975.
 72. Billings, P. B., Allen, R. W., Jensen, F. C., et al., "Anti-RNP Monoclonal Antibodies Derived From a Mouse Strain With Lupus-Like Autoimmunity," *J. Immunol.* 128:1176-1180, 1982.
 73. *Biotechnology Newswatch*, "Genentech Spurs in Secret Factor-VIII Cloning Race" 4(9):2-3, May 7, 1984.
 74. Birndorf, N. I., Lopas, H. L., and Robboy, S., "Disseminated Intravascular Coagulation and Renal Failures," *Lab. Invest.* 25:314-319, 1971.
 75. Birndorf, N. I., Lopas, H. L., and Robboy, S., "The Effects of Red Cell **Stroma-Free** Hemoglobin Solutions on Renal Function in Monkeys," *J. Appl. Physiol.* 20:573-578, 1970.
 76. Blatt, P. M., White, G. C., II, McMillan, C. W., and Webster, W. P., "Failure of Activated **Prothrombin** Complex Concentrates in a Hemophiliac With an Anti-Factor VIII Antibody," *J. A.M.A.* 251(1):67, 1984.
 77. Blattner, F. R., Williams, B. G., Blechl, A. E., et al., "**Charon Phages**: Safer Derivatives of Bacteriophage Lambda for DNA Cloning," *Science* 196:161-163, 1977.
 78. Bloom, A. L., "Benefits of Cloning Genes for Clotting Factors," *Nature* 303:474-475, 1983.
 79. Blue Cross & Blue Shield Association, "Statement on Voluntary Donation and Replacement of Blood" (Chicago, IL: Blue Cross & Blue Shield, 1972).
 80. Blumberg, B. S., Alter, H. J., and Visnich, S., "A New Antigen in Leukemia **Sera**," *J. A.M.A.* 191:541, 1965.
 81. Boggs, J. M., Clement, I. R., Moscarello, M. A., et al., "Antibody Precipitation of Lipid Vesicles Containing **Myelin** Proteins: Dependence on Lipid Composition," *J. Immunol.* 126: 1207-1211, 1981.
 82. Bolin, R., Smith, D., Moore, G., et al., "Hematologic Effects of Hemoglobin Solutions in Animals," *Advances in Blood Substitute Research*, R. B. Bolin, R. P., Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983), pp. 117-126.
 83. Bolin, R., Letterman Army Institute of Research, San Francisco, CA, personal communication, February 1984.
 84. Bolivar, F., Rodriguez, R. L., Betlach, C., et al., "Construction and Characterization of New Cloning Vehicles: 1. Ampicillin-Resistant Derivatives of the **Plasmid pMB9**," *Gene* 27:75-79, 1977.
 85. Bolivar, F., Betlach, M. C., Heyneker, H. L., et al., "Origin and Replication of **pBR345** Plasmid DNA," *Proc. Natl. Acad. Sci.* 74:5265-5269, 1977.
 86. Bolivar, F., Rodriguez, R. L., Green, J., et al., "Construction and Characterization of New

- Cloning Vehicles: II. A Multi-Purpose Cloning System," *Gene* 2:95-100, 1977.
87. Bonhard, K., "Acute Oxygen Supply by Infusion of Hemoglobin Solutions," *Fed. Proc.* 34:1466-1467, 1975.
 88. Bonhard, K., Biotest, Inc., Frankfurt, Germany, personal communication, March 1983.
 89. Boswell, G., and Rodkey, W. G., "Pharmacokinetics of Hemoglobin Infusion," *Advances in Blood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds) (New York: Alan R. Liss, Inc., 1983), pp. 139-148.
 90. Bove, J., "Improvements in Transfusion Safety: Past, Present, and Future" (abstract), CCBC 22d Annual Meeting, Feb. 26-29, 1984.
 91. Boyer, H. L., Betlack, M. C., Bolivar, F., et al., "The Construction of Molecular Cloning Vectors," *Recombinant Molecules: Impact on Science and Society*, R. F. Beer and E. Bassett (eds.) (New York: Raven Press, 1977).
 92. Bradley, T. R., and Metcalf, D., "The Growth of Mouse Bone Marrow Cells In Vitro," *Aust. J. Exp. Biol. Med. Sci.* 44:287-299, 1966.
 93. Brandt, J. L., Frank, N. R., and Lichtman, H. C., "The Effects of Hemoglobin Solutions on Renal Functions in Man," *Blood* 6:1152-1158, 1951.
 94. Broome, S., and Gilbert, W., "Immunological Screening Method to Detect Specific Translation Products," *Proc. Natl. Acad. Sci.* 75:2746-2749, 1978.
 95. Browdie, D., and Smith, H., "Stroma-free Hemoglobin: Simplified Preparation and In Vivo and In Vitro Effects on Coagulation in Rabbits," *Am. J. Surg.* 129:365-368, 1975.
 96. Brown, J. R., "Structural Origins of Mammalian Albumin," *Fed. Proc.* 35:2141-2144, 1976.
 97. Brown, M., and McCool, B. P. "Changes in the Ownership and Governance of America's Hospitals," unpublished contractor's report prepared for the Office of Technology Assessment, 1982.
 98. Brown, N., and Miller, G., "Immunoglobulin Expression by Human B-Lymphocytes Clonally Transformed by Epstein-Barr Virus," *J. Immunol.* 128:24-29, 1982.
 99. Brownstein, A., Executive Director, National Hemophilia Foundation, personal communication, Jan. 5, 1984.
 100. Brummelhuis, H. G. J., Over, J., Duivis-Vorst, C. C., et al., "Contributions to the Optimal Use of Human Blood: IX. Elimination of Hepatitis B Transmission by (Potentially) Infectious Plasma Derivatives," *Vox Sang.* 45:205-216, 1983.
 - 101a. Brunn, H. F., "Erythrocyte Destruction and Hemoglobin Catabolism," *Semin. Hematol.* 9:3-18, 1972.
 - 101b. Bucala, R., Kawakami, M., and Cerami, A., "Cytotoxicity of a Perfluorocarbon Blood Substitute to Macrophages In Vitro," *Science* 220:965-967, 1983.
 102. Busby, T. F., Atha, D. H., and Ingham, K. C., "Thermal Denaturation of Antithrombin 111. Stabilization by Herapin and Lyotropic Agents," *J. Biol. Chem.* 256:12140-12147, 1981.
 103. *BusinessWeek*, "The Red Cross: Drawing Blood From Its Rivals," Sept. 11, 1978, pp. 113, 117, 119.
 104. Bussion, R. W., and Wriston, J. C., Jr., "Influence of Incorporated Cerebrosides on the Interaction of Liposomes With Hela Cells," *Biochem. Biophys. Acta.* 471:336-340, 1977.
 106. Canadian Blood Committee, "The Four Principles Approved by the Ministers of Health," 1980.
 107. Canadian Red Cross Society Blood Transfusion Service, 1982 *Statistical Report*, Toronto, Ontario, Canadian Red Cross Society, 1982.
 108. Canadian Red Cross Society, 1982 *Annual Report*, Toronto, Ontario, Canadian Red Cross Society, 1982.
 109. Cannon, R. K., and Redish, J. R., "The Large Scale Production of Crystalline Human Hemoglobin: With Preliminary Observation on the Effect of Its Injection in Man," *Blood Substitutes and Blood Transfusion*, S. Mudd and W. Thallimer (eds.) (Springfield, IL: C. Thomas Publishers, 1942), pp. 147-155.
 110. Caplan, A., Lidz, C. W., Meisel, A., and Roth, L. H., "Mrs. X and the Bone Marrow Transplant," *Hastings Center Report* 13:17-19, June 1983.
 111. Caride, V. J., Waylor, W., Cramer, J. A., et al., "Evaluation of Liposome Entrapped Radioactive Tracers as Scanning Agents: 1. Organ Distribution of Liposome Technetium-99m Deithylenetramine Penta Acetic-Acid in Mice," *J. Nucl. Med.* 17:1067-1076, 1976.
 112. Carlson, R. W., "Albumin and Resuscitation," *American College of Surgeons 69th Annual Clinical Congress October 16-21, 1983, Postgraduate Course 1: Pre- and Postoperative Care: Blood and How to Use It*, G. S. Moss, Chair, American College of Surgeons, Chicago, IL, 1983.

113. Cerney, L. C., Cerney, E. L., and Cerney, M. E., "Mixtures of Whole Blood and Hydroxyethyl Starch-Hemoglobin Polymers," *Crit. Care Med.* 11:739-743, 1983.
114. Chandra, T., Stackhouse, R., Ridd, V. J., and Woo, S. L. C., "Isolation and Sequence Characterization of a cDNA Clone of Human Antithrombin III," *Proc. Natl. Acad. Sci.* 80:1845-1848, 1983.
115. Choo, K. H., Gould, K. G., Rees, D. J. G., et al., "Molecular Cloning of the Gene for Human Anti-haemophilic Factor IX," *Nature* 299:178-180, 1982.
116. Christman, J. K., Silverstein, S. C., and Acs, G., "Plasminogen Activators," *Proteinases in Mammalian Cells and Tissues*, A. J. Baret (ed.) (Amsterdam: Elsevier, 1977), p. 91.
117. Chung, D. W., Que, B. G., Rixon, M. W., et al., "Characterization of Complementary Deoxyribonucleic Acid and Genomic Deoxyribonucleic Acid for the Beta Chain of Human Fibrinogen," *Biochem.* 22:3244-3250, 1983.
118. Chung, D. W., Chan, W. Y., and Davie, E. W., "Characterization of a Complementary Deoxyribonucleic Acid Coding for the Gamma Chain of Human Fibrinogen," *Biochem.* 22: 3250-3257, 1983.
119. Clark, D. B., Plasma Derivatives Section, American Red Cross Blood Services Laboratory, Bethesda, MD, personal communication, February 1984.
120. Clark, G., Executive Director, American Association of Blood Banks, Arlington, VA, personal communication, 1984.
121. Clark, G., "Task Force to Study the Feasibility of a Public Education Program on AIDS and the Safety of Blood Donation and Transfusion," paper presented at the American Blood Commission Board of Directors Meeting, Washington, DC, Dec. 14, 1983.
122. Clark, L. C., Jr., and Becattini, F., "Physiology of Synthetic Blood," *J. Thorac. Cardiovasc. Surg.* 60:742-773, 1970.
123. Clark, L. C., Jr., Clark, E. W., Moore, R. E., et al., "Room Temperature-Stable Biocompatible Fluorocarbon Emulsions," *Advances in Wood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983), pp. 169-180.
124. Cline, M. J., and Golde, D. W., "Controlling the Production of Blood Cells," *Blood* 53:156-165, 1979.
125. Cochran, A., Das Gupta, T. K., De Voskin, R., et al., "Immunogenic Properties of Stroma vs. Stroma-free Hemoglobin Solution," *Surg. Forum.* 23:19-21, 1972.
126. Cohen, S., Chang, A., Boyer, H., and Helling, R., "Construction of Biologically Functional Bacterial Plasmids *in Vitro*," *Proc. Natl. Acad. Sci.* 70:3240-3244, 1973.
127. Cohn, E. J., Strong, L. E., Hughes, W. L., et al., "Preparation and Properties of Serum and Plasma Proteins: IV. A System for the Separation Into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids," *J. Am. Chem. Soc.* 68:459-475, 1946.
128. Cohn, E. J., Gurd, F. R. N., Surgenor, D. M., et al., "A System for the Separation of the Components of Human Blood: Quantitative Procedures for the Separation of the Protein Components of Human Plasma," *J. Am. Chem. Soc.* 72:465-474, 1950.
129. College of American Pathologists, "Autologous and Directed Blood Donations," reprinted in *Council of Community Blood Centers Newsletter*, Apr. 6, 1984.
130. Cohen, D., "On the Regulation and Control of Fibrinolysis," *Thromb. Haemostasis* 43:77-89, 1980.
131. Collins, J., and Hohn, B., "Cosmids: A Type of Plasmid Gene-Cloning Vector That Is Packagable *In Vitro* in Bacteriophage Lambda Heads," *Proc. Natl. Acad. Sci.* 75:4292-4245, 1978.
132. Condie, S., and Maxwell, N., "Social Psychology of Blood Donors," *Transfusion* 10:79-83, 1970.
133. Condie, S. J., Warner, W. K., and Gilman, DC, "Getting Blood From Collective Turnips: Volunteer Donation in Mass Blood Drives," *J. Appl. Psych.* 61:290-294, 1976.
134. Cook, J., "Blood and Money," *Forbes*, Dec. 11, 1978, pp. 37-38.
135. Coulombel, L., Eaves, A. C., and Eaves, C. J., "Enzymatic Treatment of Long-Term Human Marrow Cultures Reveals the Preferential Location of Primitive Hemopoietic Progenitors in the Adherent Layer," *Blood* 62:291-297, 1983.
136. Council of Community Blood Centers, *Audited Financial Statements* (Falls Church, VA: Mar. 31, 1983).
137. Council of Community Blood Banks, "San Francisco Bay Area Blood Centers Announce Anti-HBc Test Plans," *Council of Community Blood Centers Newsletter*, Apr. 6, 1984, pp. 1-2.
138. Cox, D. W., Johnson, A. M., and Fagerhol, M.

- K., et al., "Report of Nomenclature Meeting for Alpha-1-Antitrypsin," *Hum. Genet.* **53**:429-433, 1980.
139. Crawford, I. P., "Purification and Properties of Normal Human Alpha-1-Antitrypsin," *Arch. Biochem. Biophys.* **156**:215-222, 1973.
140. Crispin, J., Polyclinic Medical Center, Harrisburg, PA, personal communication, Feb. 24, 1984.
141. Cumming, P. D., Manager of Planning, Marketing, and Operations Research, Blood Services, American Red Cross, Washington, DC, personal communication, 1984.
142. Cumming, P. D., Wallace, E. L., Surgenor, D., et al., "Public Interest Pricing of Blood Services," *Medical Care* **12**:743-753, 1974.
143. Curran, J. W., et al., "Acquired Immunodeficiency Syndrome (AIDS) Associated With Transfusions," *N. Engl. J. Med.* **310**(2):69-75, 1984.
144. Dahlke, M. B., "Designated Blood Donations," *N. Engl. J. Med.* **310**(18):1195, 1984.
145. Daly, P. A., "Platelet Transfusion—Clinical Applications in the Oncology Setting," *Am. J. Med. Sci.* **280**(1):130-142, 1980.
146. Datta, N., and Kontomichalou, P., "Penicillinase Synthesis is Controlled by Infectious R Factors in Enterobacteriae," *Nature* **208**:239-241, 1965.
147. Davey, M., Assistant National Director, Blood Transfusion Service, Canadian Red Cross Society, personal communication, Jan. 9, and May 31, 1984.
148. Davie, E. W., and Fujikawa, K., "Basic Mechanisms in Blood Coagulation," *Ann. Rev. Biochem.* **44**:799-829, 1975.
149. Davis, T. A., and Asher, W. J., "Artificial Red Cells," United States Patent **4390521**, June 28, 1983.
150. Dawson, R. B., Crispin, J., Gorsuch, C., et al., "Laboratory Findings on Long-Term Plasmapheresis Donors: Protein Levels," *Proceedings of the Plasma Forum III*, W. L. Warner (ed.) (Berkeley, CA, American Blood Resources Association, 1980).
151. DeClement, F. A., and May, S. R., "Procurement, Cryopreservation and Clinical Application of Skin," *Cryopreservation of Tissue and Solid Organs for Transplantation*, A. B. Glassman and J. Umlas (eds.) (Arlington, VA, American Association of Blood Banks, 1983), pp. 29-56.
152. Denny, D., "How Organs Are Distributed," *Hastings Center Report* **13**(6):26-27, December 1983.
153. Derynck, R., Remaut, E., Saman, E., et al., "Expression of Human Fibroblast Interferon Gene in *E. coli*," *Nature* **287**:192-197, 1980.
154. Devas, R., Cheroute, H., Taya, Y., et al., "Molecular Cloning of Human Immune Interferon cDNA and Its Expression in Eukaryotic Cells," *Nucl. Acids Res.* **10**:2487-2501, 1982.
155. DeVenuto, F., Zuck, T. F., Zegna, A. I., et al., "Characteristics of Stroma-Free Hemoglobin Prepared by Crystallization," *J. Lab Clin. Med.* **89**:509-516, 1977.
156. DeVenuto, F., and Zegna, A. I., "Distinctive Characteristics of Pyridoxalated-Polymerized Hemoglobin," *Advances in Blood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983), pp. 29-40.
157. DeVenuto, F., Moores, W. Y., Zegna, A. I., et al., "Total and Partial Blood Exchange in the Rat With Hemoglobin Prepared by Crystallization," *Transfusion* **17**:555-562, 1977.
158. Dexter, T. M., Allen, T. D., and Lojtha, L. G., "Conditions Controlling the Proliferation of Hemopoietic Stem Cells *In Vitro*," *J. Cell Physiol.* **91**:335-344, 1977.
159. Dexter, T. M., Wright, E. G., Krizsa, F., et al., "Regulation of Haemopoietic Stem Cell Proliferation in Long-Term Bone Marrow Cultures," *Biomedicine* **27**:344-352, 1977.
160. Djordjevich, L., and Miller, I. F., "Synthetic Erythrocytes From Lipid Encapsulated Hemoglobin," *Exp. Hemat.* **8**:584-592, 1980.
161. Donohue, D., "Qualifications, Management, and Care of Blood Donors," *Clinical Practice of Blood Transfusion*, L. Petz and S. Swisher (eds.) (New York: Churchill Livingstone, 1981).
162. Donohue, D., Special Assistant to the Director, Center for Drugs and Biologics, U.S. Food and Drug Administration, personal communication, December 1983 and April 1984.
163. Drake, A. W., Finkelstein, S. M., and Sapolsky, H. M., *The American Blood Supply* (Cambridge: The MIT Press, 1982).
164. Drees, T. C., *Blood Plasma: The Promise and the Politics* (Port Washington, NY: Ashley Books, 1983).
165. Drees, T. C., "Can the Voluntary Blood System Replace the Paid Pheresis System?" *Plasma Quarterly* **2**(1):7, March 1980.
166. Drees, T. C., "World Wide Plasma Supply and Demand," *Plasma Forum*, R. L. Couch (ed.) (Santa Barbara, CA: McNally & Loftin, West, 1979).
167. Drees, T. C., Downing, M., and Heldebrandt, C., "Biotechnology, Here Today or Tomorrow

- row, " *Plasma Quarterly* 5(4):120-121, winter 1983.
168. Dugaicyzk, A., Law, S. W., and Dennison, O. E., "Nucleotide Sequence and the Encoded Amino Acids of Human Serum Albumin mRNA," *Proc. Natl. Acad. Sci.* 79:71-75, **1982**.
169. Dunlap, E., Department of Biotechnology, Washington University, St. Louis, MO, personal communication, Feb. 23, 1984.
170. Edlund, T., Ny, T., Ranby, M., et al., "Isolation of cDNA Sequences Coding for a Part of Human Tissue Plasminogen Activator," *Proc. Natl. Acad. Sci.* 80:349-352, **1983**.
171. Ervin, D. M., Christian, R. M., and Young, L. E., "Dangerous Universal Donors: II. Further Observations on the In Vivo and In Vitro Behavior of Isoantibodies of Immune Type Present in Group O Blood," *Blood* 5:553-567, **1950**.
172. Esterley, Michael C., Assistant Manager, Group Claims, Medicare Unit, Travelers Insurance Co., Bloomington, MN, personal communications, March and April 1984.
173. Eyster, E., Co-Medical Director, National Hemophilia Foundation, personal communication, May, 1984.
174. Fagan, J. B., Sobel, M. E., Yamada, K. M., et al., "Effects of Transformation on Fibronectin Gene Expression Using Cloned Fibronectin cDNA," *J. Biol. Chem.* 256:520-525, **1981**.
175. Fairley, N. H., "The Fate of Extracorporeal Circulating Hemoglobin," *Brit. J. Med.* 2:213-217, 1940.
176. Fantus, B., "The Therapy of Cook County Hospital," *J. A.M.A.* 109:128-131, July 10, 1937.
177. Farmer, M. C., and Gaber, B. P., "Encapsulation of Hemoglobin in Phospholipid: Surrogate Red Cells In Vitro and in Vivo," *Biophysical Journal* 45:201a, 1984.
178. Fay, P. J., Chavin, S. I., Schroeder, D., et al. "Purification and Characterization of Highly Purified Human Factor VIII Consisting of a Single Type of Polypeptide Chain," *Proc. Natl. Acad. Sci.* 79:7200-7204, **1982**.
179. *Federal Register*, 39(47):9326-9330, Mar. 8, 1974.
180. *Federal Register*, 39(176):32701-32711, Sept. 10, 1974.
181. *Federal Register*, 49 (87):18899-18900, May 3, 1984.
182. *Federal Register*, 45(213); Oct. 31, 1980.
183. Fendler, J. H., *Membrane Mimetic Chemistry* (New York, John Wiley & Sons, 1982).
184. Fendler, J. H., "Polymerized Surfactant Vesicles: Novel Membrane Mimetic Systems," *Science* 223:888-894, **1984**.
185. Feola, M., *Advances in Blood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983).
186. Ferrari, E. F., Genentech, Inc., San Francisco, CA, personal communications, February and March 1984.
187. Firkin, B. G., Arimura, G., and Barrington, W. J., "A Method for Evaluating the Hemostatic Effect of Various Agents in Thrombocytopenic Rats and Mice," *Blood* 15:388-394, **1960**.
188. Flood, A. B., Scott, W. R., and Ewy, W., "Does Practice Make Perfect? Part I: The Relation Between Hospital Volume and Outcomes for Selected Diagnostic Categories," *Medical Care* 22:98-114, **1984**.
189. Flynn, Linda S., "The Hospital Blood Bank vs. the Regional Blood Center," paper presented at the 36th Annual Meeting of the American Association of Blood Banks, New York, NY, Oct. 28-Nov. 2, 1983.
190. Ford, J. M., Cullen, M. H., Roberts, M. M., et al., "Prophylactic Granulocyte Transfusions: Results of a Randomized Controlled Trial in Patients With Acute Myelogenous Leukemia," *Transfusion* 22:311-316, **1982**.
191. Ford, J. M., Lucey, J. J., Cullen, M. H., et al., "Fatal Graft-versus-Host Disease Following Transfusion of Granulocytes From Normal Donors," *Lancet* ii:1167-1169, 1976.
192. Foss, R. D., "Using Social Psychology to Increase Altruistic Behavior: Will it Help?" *Advances in Applied Social Psychology*, vol. 3, M. Saks and L. Saxe (eds.) (Hillsdale, NJ: Erlbaum, 1984).
193. Fox, J. L., "Gene Splicing Protein to Have Orphan Drug Status," *Science* 223:914, **1984**.
194. Fox, R. C., and Swazey, J. P., *The Courage to Fail: A Social View of Organ Transplants and Dialysis* (Chicago, IL: University of Chicago Press, 1974).
195. Frank, L., and Massaro, D., "Oxygen Toxicity," *Am. J. Med.* 69:117-126, **1980**.
196. Frankl, J., Director, Administrative Services, Miller Memorial Blood Center, Bethlehem, PA, personal communication, March 1984.
197. Fratantoni, J., Center for Drugs and Biologics, U.S. Food and Drug Administration, Bethesda, MD, personal communication, April 1984.
198. Fratantoni, J., Office of Biologics Research and Review, U.S. Food and Drug Administration, Platelet Workshop, May 21-22, 1984.

199. Fried, W., "Platelets and White Blood Cells" **American College of Surgeons 69th Annual Clinical Congress October 16-21, 1983, Postgraduate Course 1: Pre- and Postoperative Care: Blood and How to Use It**, G. S. Moss, Chair, American College of Surgeons, Chicago, IL, 1983.
200. Friedlaender, G., Yale University, President, American Council on Transplantation, personal communication, Dec. 14, 1983.
201. Friedman, B. A., "Making Blood More Available," **American College of Surgeons 69th Annual Clinical Congress October 16-21, 1983, Postgraduate Course 1: Pre- and Postoperative Care: Blood and How to Use It**, G. S. Moss, Chair, American College of Surgeons, Chicago, IL, 1983.
202. Friedman, B. A., Burns, T. L., and Schork, M. A., "An Analysis of Blood Transfusion of Surgical Patients by Sex: A Quest for the Transfusion Trigger," **Transfusion** 20:179-188, 1980.
203. Friedman, B. A., Burns, T. L., and Schork, M. A., "A Study of Blood Utilization by Diagnosis, Month of Transfusion, and Geographic Region of the United States," **Transfusion** 19:511-525, 1979.
204. Friedman, B. A., Burns, T. L., and Schork, M. A., **A Study of National Trends in Transfusion Practice**, publication No. 1381125437 (Springfield, VA: National Technical Information Service, 1980).
205. Friedman, B. A., Burns, T. L., Schork, M. A., and Kalton, G., "A Description and Analysis of Current Blood Transfusion Practices in the United States With Applications for the Hospital Transfusion Committee," **Clinical Laboratory Annual, Volume 1**, Henry A. Homburger (ed.) (New York: Appleton-Century-Crofts, 1982).
206. Friedman, B. A., Schork, M. A., Mocniak, J. L., and Oberman, H. A., "Short-Term and Long-Term Effects of Plasmapheresis on Serum Proteins and Immunoglobulins," **Transfusion** 15(5):467-472, 1975.
207. Friedman, L. I., American Red Cross Blood Services Laboratory, Bethesda, MD, personal communication, 1983.
208. Friedman, L. I., "Status of Automated ABO/Rh Testing—A Cost Comparison," American Red Cross Internal Report, 1983.
209. Friedman, L. I., "Automation and Instrumentation," paper presented at the Mid-Atlantic Association of Blood Banks Annual Meeting, Baltimore, MD, Mar. 1-3, 1984.
210. Gadek, J. E., Klein, H. C., Holland, P. V., et al., "Replacement Therapy of Alpha-Antitrypsin Deficiency: Reversal of Protease-Antiprotease Imbalance Within the Alveolar Structures of PiZ Subjects," **J. Clin. Invest.** 68:1158-1165, 1981.
211. Gallo, R., Salahuddin, S. Z., Popovic, M., et al., "Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) From Patients With AIDS and at Risk for AIDS," **Science** 224:500-502, 1984.
212. Garby, L., and Noyes, W. D., "Studies on Hemoglobin Metabolism: 1. The Kinetic Properties of the Plasma Hemoglobin Pool in Normal Man," **J. Clin. Invest.** 38:1479-1483, 1959.
213. Gartner, S., and Kaplan, H., "Long-Term Culture of Human Bone Marrow Cells," **Proc. Natl. Acad. Sci.** 77:4756-4759, 1980.
214. **Genetic Engineering News**, "Chiron Develops Proprietary Hormone Process Using Yeast" 3(4):16, 1983.
215. **Genetic Engineering News**, "Integrated Genetics, Toyobo in TPA Research Contract" 3(3):24, 1983.
216. Genetics Institute, **Information Summary on the Factor VIII Project** (Boston, MA: Genetics Institute, Nov. 30, 1983).
217. Gerety, R., and Aronson, D., "Plasma Derivatives and Viral Hepatitis," **Transfusion** 22:347-351, 1982.
218. Geyer, R. P., "Whole Animal Perfusion With Fluorocarbon Suspensions," **Fed. Proc.** 29:1758-1763, 1970.
219. Geyer, R. P., Taylor, K., Duffett, E. B., et al., "Successful Complete Replacement of Blood of Living Rats With Artificial Substitutes," **Fed. Proc.** 32:927-929, 1973.
220. Giblett, E. R., "Blood Group Alloantibodies: An Assessment of Some Laboratory Practices," **Transfusion** 17:299-308, 1977.
221. Giblett, E. R., Executive Director, Puget Sound Blood Center and Program, personal communication, Feb. 10, 1984.
222. Gibson, R. M., Waldo, D. R., and Levit, K. R., "National Health Expenditures, 1982," **Health Care Financing Review** 5(1):1-31, fall 1983.
223. Gigliotti, F., and Insel, R., "Protective Human Hybridoma Antibody to Tetanus Toxin," **J. Clin. Invest.** 70:1306-1309, 1982.
224. Gilligan, D. R., Altshule, M. D., and Katersky, E. M., "Studies of Hemoglobinemia and Hemoglobinuria Produced in Man by Intravenous Injection of Hemoglobin Solutions," **J. Clin. Invest.** 20:177-187, 1941.

225. Ginsberg, M. H., Pointer, R., Forsyth, J., et al., "Thrombin Increases Expression of Fibronectin Antigen on the Platelet Surface," *Proc. Natl. Acad. Sci.* 77:1049-1053, 1980.
226. Gitschier, J., Wood, W., Goralka, T., et al., "Characterization of the Human Factor VIII Gene," *Nature* 312(5992):326-330, 1984.
227. Goeddel, D. W., Kleid, D. G., Bolivar, F., et al., "Expression in *E. Coli* of Chemically Synthesized Genes for Human Insulin," *Proc. Natl. Acad. Sci.* 76:106-110, 1979.
228. Goeddel, D., Yelverton, E., Ullrich, A., et al., "Human Leukocyte Interferon Produced by *E. Coli* is Biologically Active," *Nature* 287:411-416, 1980.
229. Goldsmith, M. F., "Liver Transplants: Big Business in Blood," *J. A.M.A.* 250(21):2905-6, Dec. 2, 1983.
230. Goodfield, J., "Vaccine on Trial," *Science* 84 5(2):78-83, March 1984.
231. Gore, A., Jr., Statement before Subcommittee on Health and the Environment, House Committee on Energy and Commerce, U.S. Congress, Hearing on H.R. 4080, The "National Organ Transplant Act," Oct. 17, 1983.
232. Gould, S. A., "Who Needs Blood," *American College of Surgeons 69th Annual Clinical Congress October 16-21, 1983, Postgraduate Course 1: Pre- and Postoperative Care: Blood and How to Use It*, G. S. Moss, Chair, American College of Surgeons, Chicago, IL, 1983.
233. Gould, S. A., Rosen, H. L., Sehgal, L. R., et al., "Assessment of a 35% Fluorocarbon Emulsion," *J. Trauma* 22:618, 1982.
234. Gould, S. A., Rosen, H. L., Sehgal, L. R., et al., "The Effect of Altered Hemoglobin-Oxygen Affinity on Oxygen Transport by Hemoglobin Solution," *J. Surg. Res.* 28:246-251, 1980.
235. Gould, S. A., Rosen, H. L., Sehgal, L. R., et al., "How Good Are Fluorocarbon Emulsions as O₂ Carriers?" *Surg. Forum* 32:299-301, 1981.
236. Grace, H. A., "Blood Donor Recruitment: A Case Study in the Psychology of Communication," *J. Soc. Psych.* 46:269-74, 1957.
237. Gray, P. W., Leung, D. W., Pennica, D. et al., "Expression of Human Immune Interferon cDNA in *E. Coli* and Monkey Cells," *Nature* 295:503-508, 1982.
238. Greenberg, A. G., Elia, C., Levine, B., et al., "Hemoglobin Solution and the Oxyhemoglobin Dissociation Curve," *J. Trauma* 15:943-950, 1975.
239. Greenberg, A. G., Newburger, P. E., and Parker, L. M., "Human Granulocytes Generated in Continuous Bone Marrow Culture Are Physiologically Normal," *Blood* 58:724-732, 1981.
240. Greenberg, A. G., Pearl, J., Balsha, J., et al., "An Improved Stroma-Free Hemoglobin Solution," *Surg. Forum* 26:53-55, 1976.
241. Greenberg, A. G., Schooley, M., and Peskin, G., "Improved Retention of Stroma-Free Hemoglobin by Chemical Modification," *J. Trauma* 17:501-504, 1977.
242. Greenwalt, T. J., Director, Paul I. Hoxworth Blood Center, University of Cincinnati Medical Center, Cincinnati, OH, personal communications, Nov. 22, Dec. 28, 1983, and Feb. 8, 1984.
243. Grenvik, A., et al., "Multiple Organ Procurement by Interhospital Transfer of Heartbeating Cadavers," G. Koostra, B. Husberg, and J. A. Vander Vliet (eds.), *Proceedings of the International Congress on Organ Procurement, Maastricht, Holland*, Apr. 14-16, 1983 (Orlando, FL: Grune & Stratton, 1984).
244. Grgicevic, D., Pistotnik, M., and Pende, B., "Observation of the Changes of Plasma Proteins After Long-Term Plasmapheresis," *Devel. Biol. Standard*, 48:279-286, 1981.
245. Grindon, A. J., Bergin, J. J., Klein, H. G., et al., "The Hospital Transfusion Committee Guidelines for Improving Practice," unpublished draft (Arlington, VA: American Association of Blood Banks Committee on Hospital Transfusion Practices, April 1984).
246. Grossman, J., and Schmitt, V., "The Plasma Derivative Market, An Overview," contract No. 433-5650.0, submitted to the Office of Technology Assessment, Washington, DC, May 1984.
247. Grunstein, M., and Hogness, D., "Colony Hybridization: A Method for the Isolation of Cloned DNAs That Contain a Specific Gene," *Proc. Natl. Acad. Sci.* 72:3961-3965, 1975.
248. Gunby, P., "Organ Transplant Group Formed," *J. A.M.A.* 250(16):2103, 1983.
249. Hackel, E., "New AABO BMTx Information Service," *American Association of Blood Banks Newsbriefs* 6(11):1-2, November/December 1983.
250. Hagen, P. J., *Blood: Gift or Merchandise* (New York: Alan R. Liss, Inc., 1982).
251. Hamilton, P. B., Huiller, H., and Van Slyke, D. D., "Renal Effects of Hemoglobin Infusions in Dogs in Hemorrhagic Shock," *J. Exp. Med.*, 86:477-487, 1947.
252. Harfst, P., Acting Director, Division of Institu-

- tional and Ambulatory Services, Office of Survey and Certification, Health Care Financing Administration, Department of Health and Human Services, Baltimore, MD, personal communication, June 1984.
253. Hayes, S. G., and Peetoom, F., *Regionalization of Blood Services: A Report on the Present Status and Future Direction*, contract No. 1-HB-6-2967, SA No. 10, submitted to the National Heart, Lung, and Blood Institute, Arlington, VA, June 30, 1981.
 254. *Head v. Colloton*, 331 N.W. 2d 870 (Iowa, 1983).
 255. Heath, D., "Genentech, Speywood Close Ranks in Move to Clone Factor VIII:C for \$400 Million Antihemophilic Market," *Biotechnology Newswatch*, vol. 2, Nov. 15, 1982.
 256. Heckler, M., Secretary, U.S. Department of Health and Human Services, Statement announcing the discovery of the possible etiologic agent for AIDS, Washington, DC, Apr. 23, 1984.
 257. Hedlund, B., Carlsson, J., Condie, R., et al. "Aspects of Large Scale Production of a Hemoglobin Band Blood Substitute," *Advances in Blood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983), pp. 71-78.
 258. Helfman, D. M., Feramisco, J., Jr., Fiddes, J. C., et al., "Identification of Clones That Encode Chicken Tropomyosin by Direct Immunological Screening of a cDNA Expression Library," *Proc. Natl. Acad. Sci.* 80:31-35, 1983.
 259. Hemphill, B., Chairman, National Committee on Clearinghouse Lifeline Program, American Association of Blood Banks, San Francisco, CA, personal communication, Mar. 22, 1984.
 260. Hennessen, W., "The Clinical Uses of Albumin: Report of an IABS Study," *Develop. Biol. Standard.* 48:49-52, 1981.
 261. Hermetter, A., and Paltauf, F., "Interaction Between Ether Glycophospholipid Vesicles and Serum Proteins in Vitro," *Biochem. Biophys. Acta.* 752:444-450, 1983.
 262. Hirsch, R. L., "Resources and Responsibility for Professional Education in Blood Transfusion Therapy," *Transfusion* 21:127-129, 1981.
 263. Hjort, P. F., Perrnan, V., and Cronkite, E. P., "Fresh, Disintegrated Platelets in Radiation Thrombocytopenia: Correction of Prothrombin Consumption Without Correction of Bleeding," *Proc. Soc. Exp. Biol. Med.* 102:31-35, 1959.
 264. Hoak, J. C., and Koepke, J. A. "Platelet Transfusions," *Clinical Practice of Blood Transfusion*, L. D. Petz and S. N. Swisher (eds.) (New York: Churchill Livingstone, 1981).
 265. Hoch, J. A., Department of Cellular Biology, Scripps Clinic and Research Foundation, La Jolla, CA, personal communications, February, March, and April 1984.
 266. Hocking, W. G., and Golde, D. W., "Long-Term Human Bone Marrow Cultures," *Blood* 56:118-124, 1980.
 267. Hogman, C. F., Akerblom, O., Hendlund, K., et al., "Red Cell Suspensions in SAGM Medium—Further Experience of *In Vivo* Survival of Red Cells, Clinical Usefulness and Plasma-Saving Effects," *Vox Sang.* 45:217-223, 1983.
 268. Hohn, B., and Murray, K., "Packaging Recombinant DNA Molecules Into Bacteriophage Particles *In Vitro*," *Proc. Natl. Acad. Sci.* 74:3259-3263, 1977.
 269. Hohn, B., and Collins, J., "A Small Cosmid for Efficient Cloning of Large DNA Fragments," *Gene* 11:291-299, 1980.
 270. Holland, Nancy B., Executive Director, American Blood Commission, Arlington, VA, personal communication, February 1983.
 - 271a. Hollinger, F. B., Mosley, J. W., Szmunes, R. D., et al., "Transfusion-Transmitted Viruses Study: Experimental Evidence for Two Non-A, Non-B Hepatitis Agents," *Journal of Infectious Diseases* 142(3):400-407, September 1980.
 - 271b. Hollinger, J., Alter, H., Holland, P., Aach, R., "Non-A, Non-B Posttransfusion Hepatitis in the United States," *Non-A, Non-B Hepatitis*, R. Gerety (cd.) (New York: Academic Press, 1981), pp. 49-70.
 272. Honda, K., Hoshimo, S., Shoji, M., et al., "Clinical Use of Blood Substitute," *N. Engl. J. Med.* 303:391-392, 1980.
 273. Huestis, D. W., Bove, J. R., and Busch, S., *Practical Blood Transfusion*, 3d ed. (Boston: Little, Brown, & Co., 1981).
 274. Huitt, R. E., Executive Director, Council of Community Blood Centers, Falls Church, VA, personal communications, Sept. 19, 1983, and Jan. 5, 1984.
 275. Humes, J. J., "Hospital Laboratory Perspective," paper presented at the Annual Meeting of the American Association of Blood Banks, New York, Oct. 28-Nov. 2, 1983.
 276. Hunt, C. A., and Burnette, R. R., "Neohemocytes," *Advances in Blood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983), pp. 71-78.

277. Hyman, L., "The Economics of Plasmapheresis by Automation: Revisited," *Plasma Quarterly* 6(1):23-24, spring 1984.
278. Igelhart, J. T., "The Politics of Transplantation," *N. Engl. J. Med.* 310(13):864-68, 1984.
279. Inkster, M., Sherman, L. A., Ahmed, P., et al., "Preservation of Antithrombin III Activity in Stored Whole Blood," *Transfusion* 24:57-59, 1984.
280. *International Blood/Plasma News*, "Pricing Trends," December 1983.
281. International Federation of Pharmaceutical Manufacturers Associations, *A Study of Commercial and Non-Commercial Plasma Procurement and Plasma Fractionation*, Zurich, Switzerland, IFPMA, 1980.
282. International Society of Blood Transfusion, *ISBT Guide 6. Blood Component Therapy*, Paris, France, International Society of Blood Transfusion, 1980.
283. Israel, L., "Staffing and Managing a Transfusion Service for Liver Transplantation," paper presented at the 36th Annual Meeting of the American Association of Blood Banks, New York, NY, Oct. 31, 1983.
284. Issitt, P. D., and Issitt, C. H., *Applied Blood Group Serology*, 2d ed. (Oxnard, CA: Spectra Biol., 1977).
285. Ivankovich, L., and Djordjevich, L., "Synthetic Erythrocytes," *Advances in Blood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983).
286. Iverson, W., Department of Research, Anheuser-Busch, Inc., St. Louis, MO, personal communication, February 1984.
287. Jackson, C. M., and Nemerson, Y., "Blood Coagulation," *Ann. Rev. Biochem.* 49:765-811, 1980.
288. Jackson, D. P., Sorenson, D. K., Cronkite, E. P., et al., "Effectiveness of Transfusions of Fresh and Lyophilized Platelets in Controlling Bleeding Due to Thrombocytopenia," *J. Clin. Invest.* 38:1689-1694, 1959.
289. Jaffe, H. W., "Transfusion-Associated AIDS: Serologic Evidence of Human T-Cell Leukemia Virus Infection of Donors," *Science* 223:1309-11, Mar. 23, 1984.
290. Jaye, M., de la Salle, H., Schamber, F., et al., "Isolation of a Human Anti-haemophilic Factor IX cDNA Clone Using a Unique 52-Base Synthetic Oligonucleotide Probe Deduced From the Amino Acid Sequence of Bovine Factor IX," *Nucl. Acid Res.* 11:2325-2335, 1983.
291. Johnson, D. B. (cd.), *Blood Policy: Issues and Alternatives*, papers presented at a Conference on Blood Policy sponsored by the American Enterprise Institute, Washington, DC, 1976.
292. Jonah, M. M., Carny, E. A., and Rahman, Y. E., "Tissue Distribution of EDTA Encapsulated Within Liposomes Containing Glyco Lipids or Brain Phospholipids," *Biochem. Biophys. Acta.* 541:321-329, 1978.
293. Jones, P., "Factor VIII Supply and Demand," *Brit. Med. J.* 280:1531-1532, 1980.
294. Kagawa, Y., "Reconstruction of the Energy Transformer Gate and Channel Subunit Reassembly Crystalline ATPase and ATP Synthesis," *Biochem. Biophys. Acta.* 505:45-52, 1978.
295. Kahn, R., "Remarks in Questions and Answers," in W. L. Warner (cd.), *Plasma Forum III* (Feb. 25-27, 1980) (Berkeley, CA: American Blood Resources Association, 1980), pp. 127-130.
296. Kahn, R., "Establishing a Tissue Bank in a Blood Collection Facility: An Introduction to Bone Banking," *Cryopreservation of Tissue and Solid Organs for Transplantation*, A. B. Glassman and J. Umlas (eds.) (Arlington, VA: American Association of Blood Banks, 1983).
297. Kahn, R., Allen, R., Baldassare, J., and Cheetham, P., *Alternate Sources and Substitutes for Therapeutic Blood Components* contract No. 433-2390.0, submitted to the Office of Technology Assessment, Mar. 6, 1984.
298. Kane, W. H., Lindhout, M. J., Jackson, C. M., et al., "Factor V: Dependent Binding of Factor Xa to Human Platelets," *J. Biol. Chem.* 255:1170-1174, 1980.
299. Karow, A. M., and Glassman, A. B., "Should Blood Banks Become Organ Banks," *Transfusion* 15:285-286, 1975.
300. Kasahara, M., and Hinkle, P. C., "Reconstitution of D-Glucose Transport Catalyzed by a Protein Fraction From Human Erythrocytes in Sonicated Liposomes," *Proc. Natl. Acad. Sci.* 73:376-400, 1977.
301. Katz, A. J., Genco, P. V., Blumberg, N., et al., "Platelet Collection and Transfusion Using the Fenwal CS-3000 Cell Separator," *Transfusion* 21:560-563, 1981.
302. Katz, A., American Red Cross National Headquarters, Information on Donation Trends presented to the AIDS Working Group; Division of Blood Diseases and Resources; National Heart, Lung, and Blood Institute, Bethesda, MD, Mar. 5, 1984.
303. Keefer, L. M., Piron, M. A., and De Meyto, P., "Human Insulin Prepared by Recombinant

- DNA Techniques and Native Human Insulin Interact Identically With Insulin Receptors, " *Proc. Natl. Acad. Sci.* **78**:1391-1395, 1981.
304. Kekkar, V., "Low Dose Heparin in the Prevention of Venous Thromboembolism—Rationale and Results, " *Thromb. Diath. Haemorrh.* **33**:87-96, 1974.
 305. Kelley, W., Biogen, Inc., Boston, MA, personal communication, February 1984.
 306. Kellner, A., President, New York Blood Center, personal communication, 1984,
 307. Kennedy, L., "Community Blood Banking in the United States From 1937-1975: Organizational Formation, Transformation and Reform in a Climate of Competing Ideologies," Ph.D. dissertation, New York University, 1978.
 308. Kessler, C., Department of Hematology and Oncology, George Washington University Medical Center, Washington, DC, personal communication, Dec. 1, 1983.
 309. Kimelberg, H. K., "Differential Distribution of Liposome-Entrapped (³H) Methotrexate and Labelled Lipids After Intravenous Injection in a Primate, " *Biophys. Acta.* **448**:531-550, 1976.
 310. Kimelberg, H. K., and Mayhew, E. G., "Properties and Biological Effects of Liposomes and Their Uses in Pharmacology and ToxicologyJ" *CRC Crit. Res. Toxicol.* **6**:25-103, 1978.
 311. Kirby, C., Clarke, J., and Gregoriadis, G., "Effect of the Cholesterol Content of Small Unilamellar Liposomes on Their Stability *In Vivo* and *In Vitro*, " *Biochem. J.* **186**:591-598, 1980.
 312. Kitazawa, M., and Ohnishi, Y., "Long Term Experiment of Perfluorochemicals Using Rabbits," *Virchows Arch. A.* **398**:1-10, 1982.
 313. Klein, E., Farber, S., Freeman, G., et al., "The Effects of Varying Concentrations of Human Platelets and Their Stored Derivatives on the Decalcification Time of Plasma," *Blood* **11**:910-919, 1956.
 314. Klein, E., Tech, R., Farber, S., et al., "Hemostasis in Thrombocytopenic Bleeding Following Infusion of Stored, Frozen Platelets, " *Blood* **11**:693-699, 1956.
 315. Klein, H., "Problems and Perspectives in Blood Banking, " paper presented to the Interagency Technical Committee Working Group on Blood and its Substitutes, National Institutes of Health, Bethesda, MD, Mar, 25, 1981.
 316. Klein, S. J., Secretary, New York State Council on Human Blood and Transfusion Services, Center for Laboratories and Research, Department of Health, Albany, NY, personal communication, Apr. 18, 1984.
 317. Klein, T., "The Politics of Plasma, " *Plasma Quarterly* **2**(1):6-7, 29, March 1980.
 318. Kohler, G., and Milstein, C., "Continuous Cultures of Fused Cells Secreting Antibody of Predefine Specificity," *Nature* **256**:495-497, 1975.
 319. Kolins, J., Britten, A., and Silvergleid, A. J. (eds.), *Plasma Products: Use and Management* (Arlington, VA: American Association of Blood Banks, 1982).
 320. Konig, J., First Secretary, Embassy of the Federal Republic of Germany, personal communication, Jan. 11, 1984.
 321. Kozbor, D., Lagarde, A. E., and Roder, J. C., "Human Hybridomas Constructed With Antigen-specific Epstein-Barr Virus-Transformed Cell Lines," *Proc. Natl. Acad. Sci.* **79**:6651-6655, 1982.
 322. Krauthammer, C., "The Politics of a Plague," *The New Republic* **189**(5):18-21, Aug. 1, 1983.
 323. Kurachi, K., Chandra, T., Friezner Degen, S. J., et al., "Cloning and Sequence of cDNA Coding for Alpha-1 -antitrypsin," *Proc. Natl. Acad. Sci.* **78**:6826-6830, 1981.
 324. Kushwaka, S. C., Kates, M., and Martin, W. G., "Characterization and Composition of the Purple and Red Membranes From *Halobacterium cutirubrum*, " *Can. J. Biochem.* **53**:284-291, 1975.
 325. Kushnik, H., "A Mother Tells How a Blood Donation, The Gift of Life, Led to Her Young Son's Death From AIDS," *People* **21**(22):62-68, June 4, 1984.
 326. Lachs, J., "On Selling Organs," *Forum on Medicine* **2**(11):746-7, November 1979.
 327. Landfield, R., Brief of American Blood Resources Association and Florida Association of Plasmapheresis Establishments as *Amici Curiae*, in *Automated Medical Laboratories, Inc. v. Hillsborough County*, No. 83-3014, U.S. Court of Appeals, 11th Circuit, July 8, 1983, p. 9.
 328. Landfield, R., "A Quick Look at the Joint Venture," *Plasma Quarterly* **1**(1):11, 28-29, February 1979.
 329. Landfield, R., "Red Cross Plasma Business and Federal Taxes," *Plasma Quarterly* **1**(4) :100-101, December 1979.
 330. Landfield, R., General Counsel, American Blood Resources Association, and Partner, Landfield, Becker & Green, personal communication, Nov. 22, 1983.
 331. Landsteiner, K., and Weiner, A. S., "An Agglutinable Factor in Human Blood Recognized by Immune Sera for Rhesus Blood, " *Proc. Soc. Exp. Bio. Med.* **43**:223, 1940.

332. Larrick, J. W., Truitt, K. E., Raubitschek, A. A., et al., "Characterization of Human Hybridomas Secreting Antibody to Tetanus Toxoid," *Proc. Natl. Acad. Sci.* 80:6376-6380, 1983.
333. Latham, W., "The Renal Excretion of Hemoglobin: Regulatory Mechanisms in the Differential Excretion of Free and Plasma-Bound Hemoglobin," *J. Clin. Invest.* 38:652-658, 1959.
334. Lau, P., Shankar, V. S., Mayer, L. L., et al., "Coagulation Defects After Infusion of Dispersed Fluorochemicals," *Transfusion* 15:432-438, 1975.
335. Lauren, C. B., and Jeppsson, J. O., in F. W. Putnam (cd.), *The Plasma Protein*, 2d cd., vol. 1 (New York: Academic Press, 1975), pp. 229-264.
336. Lawn, R. M., Adelman, J., Bock, S. C., et al., "The Sequence of Human Serum Albumin cDNA and Its Expression in *E. coli*," *Nucl. Acids. Pres.* 9:6103-6144, 1981.
337. Leclerc-Chevalier, D., Executive Director, Canadian Blood Committee, personal communication, June 1984.
338. Leder, P., Tiemeier, D., and Enquist, L., "EK2 Derivatives of Bacteriophage Lambda Useful in the Cloning of DNA From Higher Organisms: The Lambda gtWES System," *Science* 196:175-178, 1977.
339. Legaz, M. E., Schmer, G., Counts, R. G., et al., "Isolation and Characterization of Human Factor VIII (Antihemophilic Factor)," *J. Biol. Chem.* 248:3926, 1973.
340. Lehninger, A. L., "Biochemistry: The Molecular Basis of Cell Structure and Function" (New York: Worth Publishers, 1970).
341. Levine, C., "Blood: Designated Gifts, Experimental Therapy, and Racial Labels," *Hastings Ctr. Rep.* 13(4):3-4, August 1983.
342. Levine, P., and Stetson, R., "An Unusual Case of Intra-Group Agglutination," *J. A.M.A.* 113:126-127, 1939.
343. Levy, S. B., McMurray, L., Onigman, P., and Saunders, R. M., "Plasmid-Mediated Tetracycline Resistance in *E. coli*," *Topics in Infectious Disease*, J. Drews and G. Hagnauer (eds.) (New York: Springer-Verlag, 1978).
344. Lewisohn, R., "Blood Transfusion by the Citrate Method," *Surg. Gynecol. Obstet.* 21:37-47, 1915.
345. Lovric, V. A., Schuller, M., Bryant, J., et al., "Better Erythrocyte Concentrates—More Plasma for Components," *Med. J. Australia* 1:635-637, 1981.
346. Lundsgaard-Hansen, P., "Donor Safety in Plasmapheresis," *Develop. Biol. Standard* 48:287-295, 1981.
347. Lundsgaard-Hansen, P., "Intensive Plasmapheresis," *Transfus. Int.* 21(2):1:(8-10), April 1980.
348. Lundsgaard-Hansen, P., "Impact of the Protein Content of Red Cell Concentrates on the Optimum Use of Blood," *Vox. Sang.* 37:65-72, 1979.
349. Lundsgaard-Hansen, P., Pappova, E., and Frei, E., "Clinical Indications for Human Serum Albumin," *Develop. Biol. Standard* 48:69-74, 1981.
350. Lutz, J., Barthel, U., and Metzner, P., "Variation in Toxicity of *E. coli* Endotoxin After Treatment With Perfluorated Blood Substitutes in Mice," *Circ. Shock* 9:99-106, 1982.
351. McPherson, J., Assistant Director, Regional Hemophilic Blood Services, National Headquarters, American Red Cross Blood Services, personal communication, Washington, DC, Feb. 6, 1984.
352. Malcolm, A. D. B., "The Use of Restriction Enzymes in Genetic Engineering," *Genetic Engineering*, vol. 2, R. Williamson (cd.) (New York: Academic Press, 1981), pp. 129-173.
353. Maniatis, T., Kee, S. G., Efstratiades, A., and Kafato, F. C., "Amplification and Characterization of a B-globin Gene Synthesized *In Vitro*," *Cell* 8:163-182, 1976.
354. Maples, J., U.S. Naval Research Institute, Bethesda, MD, personal communication, March 1984.
355. Marguerie, G. A., Edgington, T. S., and Plow, E. F., "Interaction of Fibrinogen With Its Platelet Receptor as Part of a Multistep Reaction in ADP-Induced Platelet Aggregation," *J. Biol. Chem.* 255:154-161, 1980.
356. Marketing Research Bureau, Inc., "The Plasma Fractions Market in the United States, 1982," *The Marketing Research Bureau, Inc.*, Newport Beach, CA, 1983.
357. Marks, D., Letterman Army Institute of Research, San Francisco, CA, personal communication, February 1984.
358. Mauch, P., Greenberger, J. S., Botneck, L. E., et al., "Evidence for Structured Variation in the Self-Renewal Capacity of Hemopoietic Stem Cells Within Long-Term Bone Marrow Cultures," *Proc. Natl. Acad. Sci.* 77:2927-2930, 1980.
359. Mauk, M. R., Gamble, R. C., and Baldeschwiller, J. S., "Targeting of Lipid Vesicles: Specificity of Carbohydrate Receptor Analogues for Leukocytes in Mice," *Proc. Natl. Acad. Sci.* 77:4430-4434, 1980.
360. Mayer, K., Chair, Blood Services Committee, New York State Council on Human Blood and

- Transfusion Services, Albany, NY, personal communications, Nov. 8, 1983, and Mar. 15, 1984.
361. Mayhew, E., and Papahadjopoulos, D., "Therapeutic Applications of Liposomes," *Liposomes*, M. J. Ostro (ed.) (New York: Marcel Dekker, Inc., 1983).
 362. McCabe, J. M., Legislative Director, National Conference of Commissioners on Uniform State Laws, statement before Subcommittee on Investigations and Oversight, House Committee on Science and Technology, U.S. Congress, hearings on organ transplants, Apr. 5, 1983.
 363. McCurdy, P., Chairman, Public Education Committee, American Red Cross Blood Services, Washington Region, personal communication, February 1984.
 364. McCurdy, P. R., Alexandria, VA, personal communication, June 1984.
 365. McGill, M., Fugman, D., and Vittorio, N., "Platelet Membrane Concentrates Stored for Six Months Decreased Bleeding Times in Thrombocytopenic Rabbits," *Transfusion* 23:414, 1983.
 366. McGill, M., Associate Director for Scientific Development, Paul Hoxworth Blood Center, Cincinnati, OH, personal communication, April 1983.
 367. McLaughlin, W. F., "Membrane Hemapheresis: A Cost Effective Approach to a Two Tiered Market," unpublished, 1983.
 368. McShane, D. J., and Schram, N. R., "Cause of Acquired Immune Deficiency Syndrome" (letter), *J. A.M.A.* 251(3):341, 1984.
 369. Medical and Technical Staff of the Aurora Area Blood Bank, *Circular of Information on the Use of Blood and Blood Components* (Aurora, IL: Aurora Area Blood Bank, 1983).
 370. Mega, T., Lujan, E., and Yoshida, A., "Studies on the Oligosaccharide Chains of Human Alpha-1-proteinase Inhibitor," *J. Biol. Chem.* 255:4057-4061, 1980.
 371. Meloun, B., Moravek, L., and Kosta, V., "Complete Amino Acid Sequence of Human Serum Albumin," *FEBS Letters* 58:134-137, 1975.
 372. Memorial Sloan Kettering Cancer Center, "Blood Bank, Donor Room, Special Procedures, Hematology and Urinalysis Laboratories Annual Report, 1983," unpublished manuscript, 1983.
 373. Menache-Aronson, D., Associate Director, Plasma and Plasma Derivative Services, Blood Services Laboratories, American Red Cross, personal communication, June 1984.
 374. Merritt, R. A., "State Legislation Relating to Organ Transplantation," paper presented to meeting of the American Council on Transplantation, Arlington, VA, Jan. 23, 1984.
 375. Mertz, J. E., and Davis, R. W., "Cleavage of DNA by R1 Restriction Endonuclease Generates Cohesive Ends," *Proc. Natl. Acad. Sci.* 69:3370-3374, 1972.
 376. Meryman, H., American Red Cross, Washington, DC, personal communication, December 1983.
 377. Messmer, K., Jesch, F., and Schaff, J., "Oxygen Supply by Stroma-Free Hemoglobin," *Prog. Clin. Biol. Res.* 19:175-190, 1978.
 378. Meyer, D., McKee, P. A., Noyer, L. W., et al., "Molecular Biology of Factor VIII/von Willebrand Factor," *Thrombosis Haemostas* 40:245-251, 1978.
 379. Meynell, E., and Datta, N., "Mutant Drug Resistance Factors of High Transmissibility," *Nature* 241:885-886, 1967.
 380. Miletich, J. P., Jackson, C. M., and Majerus, P. W., "Properties of the Factor Xa Binding Site on Human Platelets," *J. Biol. Chem.* 253:6908-6916, 1978.
 381. Miller, J. H., and McDonald, R. K., "The Effect of Hemoglobin on Renal Function in the Human," *J. Clin. Invest.* 30:1033-1040, 1951.
 382. Miller, T., and Weikel, M. K., "Blood Donor Eligibility, Recruitment and Retention," in American Red Cross, *Selected Readings in Donor Motivation and Recruitment*, vol. 2 (Baltimore: Reese Press, 1974).
 383. Miller, W. V., American Red Cross, St. Louis, MO, President, American Blood Commission, personal communications, March and April 1984.
 384. Mitsuno, T., Okyanagi, H., and Naito, R., "Clinical Studies of a Perfluorochemical Whole Blood Substitute (Fluosol-DA)," *Ann. Surg.* 195:60-69, 1982.
 385. Modrich, P., "Structures and Mechanisms of DNA Restriction and Modification Enzymes," *Q. Rev. Biophys.* 12:315-369, 1979.
 386. Mok, W., Chen, D. E., and Mazur, A., "Cross-Linked Hemoglobins as Potential Protein Expanders," *Fed. Proc.* 34:1458-1460, 1975.
 387. Mollison, P. L., *Blood Transfusion in Clinical Medicine*, 6th ed. (Oxford: Blackwell Scientific Publications, 1979).
 388. Mollison, P. L., *Blood Transfusion in Clinical Medicine*, 7th ed. (Oxford: Blackwell Scientific Publications, 1983).
 389. Moore, F. D., *Transplant: The Give and Take*

- of Tissue Transplantation (New York: Simon & Schuster, 1972).
390. Moore, M. A. S., Sheridan, A. P. C., Allen, T. D., et al., "Prolonged Hematopoiesis in a Primate Bone Marrow Culture System: Characteristics of Stem Cell Production and the Hematopoietic Microenvironment," *Blood* 54:775-793, 1979.
 391. Morgan, Lewis & Bockius, Attorneys for American National Red Cross, *Memorandum Re: Joint Venture for the Construction, Ownership and Operation of a Fractionation Facility*, submitted to the Antitrust Division, U.S. Department of Justice, Apr. 25, 1978.
 392. Moroff, G., and Dende, D., "The Additive Solution System Approach to Blood Preservation and Component Preparation," Technical Report for the American Red Cross, 1983.
 393. Morrisett, J. D., Jackson, R. L., and Gotto, A. M., "Lipid Protein Interactions in the Plasma Lipoproteins," *Biochem. Biophys. Acta.* 472:93-133, 1977.
 394. Moss, G. S., "Crystalloids and Resuscitation" *American College of Surgeons 69th Annual Clinical Congress October 16-21, 1983, Postgraduate Course 1: Pre- and Postoperative Care: Blood and How to Use It*, G. S. Moss, Chair, American College of Surgeons, Chicago, IL, 1983.
 395. Moss, G. S., Letter in Questions and Answers Column, *J.A.M.A.*, 250:2211, 1983.
 396. Moss, G. S., and DeWoskin, R., Rosen, A. L., et al., "Transport of Oxygen and Carbon Dioxide by Hemoglobin-Saline Solution in the Red Cell-Free Primate," *Surg. Gynecol. Obstet.* 142:357-362, 1976.
 397. Murray, C., and Tishkoff, G. H., "Preparation of Components and Their Characteristics; Plasmapheresis and Cytapheresis," *Clinical Practice of Blood Transfusion*, L. D. Petz and S. N. Swisher (eds.) (New York: Churchill Livingstone, 1981).
 398. Nagata, S., Taira, H., Hall, A., et al., "Synthesis in *E. coli* of a Polypeptide With Human Leukocyte Interferon Activity," *Nature* 284:316-320, 1980.
 399. National Hemophilia Foundation, Medical and Scientific Advisory Council, "Recommendations to Prevent AIDS in Patients With Hemophilia," *Medical Bulletin #9: Chapter Advisory #12* (New York: National Hemophilia Foundation, Oct. 22, 1983).
 400. National Hemophilia Foundation, *State and Federal Resources Guide for Hemophiliacs* (New York: National Hemophilia Foundation, 1979).
 401. National Hemophilia Foundation, 1982 *Annual Report* (New York: National Hemophilia Foundation, 1982).
 402. Navota, R., President, Mississippi Valley Regional Blood Center, personal communication, March 1984.
 403. Nemo, G. J., Chief, Blood Resources Branch, Division of Blood and Blood Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, personal communications, March and May 1984.
 404. Ness, P. M., and Pennington, R. M., "Plasma Fractionation in the United States: A Review for Clinicians," *J. A.M.A.* 230:247-250, 1974.
 405. New York Cytapheresis Task Force, "Cytapheresis Practice," *NY St. J. Med.* October 1982.
 406. New York Times, "Red Cross and Laboratory Plan Blood Plasma Facility," Mar. 16, 1979, p. A14.
 407. Nusbacher, J., "Transfusion of Red Blood Cell Products," *Clinical Practice of Blood Transfusion*, L. D. Petz and S. N. Swisher (eds.) (New York: Churchill Livingstone, 1981).
 - 408a. Nusbacher, J., and Bove, J., "Rh Immunoprophylaxis: Is Antepartum Therapy Desirable?" *N. Engl. J. Med.* 303:935, 1980.
 - 408b. Oberman, H. A., Barnes, B. A., and Friedman, B. A., "The Risk of Abbreviating the Major Crossmatch in Urgent or Massive Transfusion," *Transfusion* 18:137-41, 1978.
 409. Obome, D. J., Bradley, S., and Lloyd-Griffiths, M., "The Anatomy of a Volunteer Blood Donation System," *Transfusion* 18(40):458-465, 1978.
 410. Odegaard, O., and Abildgaard, U., "Anti-thrombin III: Critical Review of Assay Methods: Significance of Variation in Health and Disease," *Haemostasis* 7:127-134, 1978.
 411. Ogawa, M., Porter, P. N., and Nakahata, T., "Renewal and Commitment to Differentiation of Hemopoietic Stem Cells (An Interpretive Review)," *Blood* 61:823-829, 1983.
 412. O'Hara, John L., Jr., Associate Regional Administrator, Division of Program Operations, Health Care Financing Administration, Region IX, U.S. Department of Health and Human Services, personal communication, April 1984.
 413. Ohyanagi, H., Toshima, K., Mitsuno, T., et al., "Clinical Studies of Perfluorochemical Whole Blood Substitutes: A Safety of Fluosol-DA in

- Normal Human Volunteers, " *Clin. Therap.* 2:306-312, 1979.
- 414a. Olsson, L., and Kaplan, H., "Human-Human Hybridomas Producing Monoclonal Antibodies of Predefine Antigenic Specificity," *Proc. Natl. Acad. Sci.* 77:5429-5431, 1980.
 - 414b. *On Center 1:2* (Emeryville, CA: Cutter Biological, 1983).
 415. O'Shaughnessy, L., Mansell, H. E., and Slome, D., "Hemoglobin Solution as a Blood Substitute," *Lancet* ii:1068-1069, 1939.
 416. Osterud, B., Bouma, B. N., and Griffin, J. H., "Human Blood Coagulation Factor IX: Purification, Properties and Mechanism of Activation by Activated Factor XI," *J. Biol. Chem.* 253:5946-5951, 1978.
 417. Oswalt, R. M., "A Review of Blood Donor Motivation and Recruitment," *Transfusion* 17(2):123-35, March / April 1977.
 418. Ottenberg, R., and Fox, C. L., "The Rate of Removal of Hemoglobin From the Circulation and Its Renal Threshold in Human Beings," *Am. J. Physiol.* 123:516-525, 1938.
 419. Over, J., Oh, J., Henrichs, H., et al., "The Effects of the Cooling Rate During Freezing of Plasma on Solute Concentration and Factor VIII Recovery in Cryoprecipitates," *Abstracts of the International Society of Thrombosis and Haemostasis, Abstract No. 0320* (Stockholm, Sweden: July 5, 1983).
 420. Page, P., American Red Cross Blood Services, Northeast Region, Boston, MA, personal communication, June 1984.
 421. Parise, L. V., and Phillips, D. R., "Reconstitution of Platelet Membrane Glycoproteins IIb and IIIa Into Phospholipid Vesicles," abstract #961 presented at the American Society of Hematology Meeting, San Francisco, 1983, *Blood* 62:264a, 1983.
 422. Pennica, D., Holmes, W., Kohr, W. J., et al., "Cloning and Expression of Human-Tissue Type Plasminogen Activator cDNA in *E. coli*," *Nature* 301:214-221, 1983.
 423. Perutz, M. F., "Regulation of Oxygen Affinity of Hemoglobin: Influence of Structure of the Globin on the Heme Iron," *Ann. Rev. Biochem.* 48:327-386, 1979.
 424. Peskin, G. W., O'Brien, K., and Rabiner, S. F., "Stroma-Free Hemoglobin Solution: The 'Ideal' Blood Substitute?" *Surgery* 66:185-193, 1969.
 425. Petersdorf, R. G., Adams, R. D., Braunwald, E., et al. (eds.), *Harrison's Principles of Internal Medicine*, 10th ed. (New York: McGraw Hill, 1983).
 426. Peterson, T. E., Dudek-Wojciechowska, G., Scottrup-Jensen, L., et al., "Primary Structure of Antithrombin III (Heparin Co-Factor): Partial Homology Between Alpha-1 -Antitrypsin and Antithrombin III," *The Physiological Inhibitors of Blood Coagulation and Fibrinolysis*, D. Cohen, B. Wiman, B. Verstraete, and M. Verstraete (eds.) (Amsterdam: Elsevier, 1979), pp. 43-54.
 427. Petrie, G. E., and Jonas, A., "Spontaneous Phosphatidylcholine Exchange Between Small Unilamellar Vesicles and Lipid-Apolipoprotein Complexes and Effects of Particle Concentrations and Compositions," *Biochemistry* 23:720-725, 1984.
 428. Petska, S., "The Purification and Manufacture of Human Interferon," *Scientific American* 249:37-43, 1983.
 429. Petz, L. D., and Swisher, S. N., *Clinical Practice of Blood Transfusion* (New York: Churchill Livingston, 1981).
 430. Phillips, R. A., Gilder, R., Killough, J. H., et al., "The Results of Sixty-two Large Volume Hemoglobin Infusions in Man," *Res. Proj. NM 007-082.02,01*, U.S. Navy Medical Unit No. 3, Cairo, Egypt, 1951.
 431. Pickering, J. W., and Gelder, F. B., "A Human Myeloma Cell Line That Does Not Express Immunoglobulin But Yields a High Frequency of Anti-Body-Secreting Hybridomas," *J. Immunol.* 129:406-411, 1982.
 432. Pickering, L., "Roslyn Country Club Civic Association's First Drive a Success," *The Donor* (New York: Greater New York Blood Program, winter 1984), p. 1.
 433. Piliavin, J. A., Callero, P. L., and Evans, D. E., "Addiction to Altruism? Opponent Process Theory and Habitual Blood Donation," *J. of Personality and Soc. Psych.* 43:1200-13, 1982.
 434. Pindyck, J., Gaynor, S., Hirsch, R., et al., "Prevention of Infection Transmission by Transfusable Blood, Blood Components or Plasma Derivatives," contract No. 433-2900.0, submitted to the Office of Technology Assessment, Washington, DC, 1984.
 435. Pittiglio, D. H., Baldwin, A. J., Sohmer, P. R. (eds.), *Modern Blood Banking and Transfusion Practices* (Philadelphia, PA: F. A. Davis Co., 1983).
 436. Plapp, F. V., and Sinor, L. T., "Nonisotopic Immunoassays in Blood Group Serology," *A Seminar on Antigen-Antibody Reactions Revisited*, C. A. Bell (ed.) (Arlington, VA: American Association of Blood Banks, 1982).

437. *Plasma Quarterly*, "About ABRA" 5(2):35, spring 1983.
438. *Plasma Quarterly*, "Red Cross to Pay Taxes" 4(1):17, winter 1982.
439. *Plasma Quarterly*, "Understanding Plasma" 6(2):36-38, summer 1984.
440. Poindexter, B., Office of Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, personal communication, February 1984.
441. Polisky, B., Bishop, R. J., and Gelfand, D. H., "A Plasmid Vehicle Allowing Regulated Expression of Eukaryotic DNA in Bacteria," *Proc. Natl. Acad. Sci.* 73:3900-3904, 1976.
442. Pool, J., Hershgold, E., and Pappenhagen, A., "High-Potency Antihaemophilic Factor Concentrate From Cryoglobulin Precipitate," *Nature* 203:312, 1964.
443. Pool, J., and Shannon, A., "Production of High-Potency Concentrates of Antihemophilic Globulin in a Closed-bag System," *N. Engl. J. Med.* 273:1443-1447, 1965.
444. Popovic, M., Sarngadharan, M. G., Read, E., and Gallo, R. C., "Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) From Patients With AIDS and Pre-AIDS," *Science* 224:497-500, 1984.
445. Power, E. J., "AIDS and the San Francisco Blood Supply," contract No. 433-4520.0, submitted to the Office of Technology Assessment, Washington, DC, April 1984.
446. Prasanna, H. R., Edwards, H. H., and Phillips, D. R., "Interaction of Platelet Plasma Membranes With Thrombin-Activated Platelets," *Blood* 57:305-312, 1981.
447. Prince, A., Stephan, W., and Brotman, B., "Inactivation of Non-A, Non-B Virus Infectivity by a Beta-Propiolactone/Ultraviolet Irradiation Treatment and Aerosil Adsorption Procedure Used for Preparation of a Stabilized Human Serum," *Vox Sang.* 46(2):80-85, 1984.
448. Prochownik, E. V., Markham, A. F., and Orkin, S. H., "Isolation of a cDNA Clone for Human Antithrombin III," *J. Biol. Chem.* 258: 8389-8394, 1983.
449. Proffitt, R. T., Williams, L. E., Presant, C. A., et al., "Liposomal Blockage of the Reticuloendothelial System: Improved Tumor Imaging With Small Unilamellar Vesicles," *Science* 220: 502-505, 1983.
450. Prottas, J. M., "Encouraging Altruism: Public Attitudes and the Marketing of Organ Donation," *Milbank Mere, Fund Q.* 61(2):278-306, spring 1983.
451. Prottas, J. M., Visiting Professor, Center for Health Policy Analysis and Research, Brandeis University, personal communication, Jan. 5, 1984.
452. Pura, L., et al., "Directed Donor Program: A Three-Fold Benefit," paper presented at the AABB 36th Annual Meeting, New York, Nov. 1, 1983.
453. Quick, A. J., Goergotsos, M. S., and Hussen, C. B., "The Clotting Activity of Human Erythrocytes: Theoretical and Clinical Implications," *Am. J. Med. Sci.* 2208:207-213, 1954.
454. Rabiner, S. F., and Friedman, L. H., "The Role of Intravascular Haemolysis and the Reticulo-Endothelial System in the Production of a Hypercoagulable State," *Brit. J. Haematol.* 14:105-118, 1968.
455. Rabiner, S. F., Helbert, J. R., Lopas, H., et al., "Evaluation of a Stroma-Free Hemoglobin Solution for Use as a Plasma Extender," *J. Exp. Med.* 126:1127-1142, 1967.
456. Racker, E., and Stoeckenius, W., "Reconstitution of Purple Membrane Vesicles Catalyzing Light-Driven Protons Uptake and Adenosine Triphosphate Formation," *J. Biol. Chem.* 249: 662-663, 1974.
457. Randolph, H. B., "The Future Shocks to Blood Banking Economics," paper presented at the South Central Association of Blood Banks Annual Meeting, Albuquerque, NM, Feb. 19-22, 1984.
458. Reijngoud, D. J., and Phillips, M. C., "Mechanisms of Dissociation of Human Apolipoproteins A-I, A-II, and C From Complexes With Dimyristoylphosphatidylcholine As Studied by Thermal Denaturation," *Biochem.* 13:726-734, 1984.
459. Reilly, R. W., Executive Director, American Blood Resources Association, Annapolis, MD, personal communications, Dec. 9, 1983, and Jan. 5, 1984.
460. Rettig, R. A., testimony before Subcommittee on Investigations and Oversight, House Committee on Science and Technology, U.S. Congress, hearings on organ transplants, Apr. 13, 14, and 27, 1983.
461. Rijken, D. C., and Cohen, D., "Purification and Partial Characterization of Plasminogen Activator Secreted by Human Melanoma Cells in Culture," *J. Biol. Chem.* 256:7035-7041, 1981.
462. Rixon, M. W., Chan, Y. W., Davie, E. W., et al., "Characterization of a Complementary Deoxyribonucleic Acid Coding for the Alpha Chain of Human Fibrinogen," *Biochem.* 22:3237-3244, 1983.
463. Robin-Tani, M., "Kidneys for Sale: The Con-

- troversty Surrounding Dr. H. Barry Jacobs and the National Organ Transplant Act," *Contemporary Dialysis* 4(11):21-41, 1983.
464. Rodell, M. B., Vice-president, Regulatory and Technical Affairs, Ethical Products Division, Revlon Health Care Group, personal communication, Dec. 27, 1983.
 465. Romano, M., Public Affairs Director, Broward County Blood Center, **Lauderhill**, FL, personal communication, August 1984.
 466. Rosen, J., Vice President and General Manager, **Sera-Tec Biological**, North Brunswick, NJ, personal communication, 1984.
 467. Rosenoer, V., Oratz, M., and Rothschild, M. (eds.), *Albumin Structure, Function, and Uses* (Oxford: Pergamon Press, 1977).
 468. Roshenshein, M. S., Farewell, V. T., Price, T. H., et al., "The Cost Effectiveness of Therapeutic and Prophylactic Leukocyte Transfusion," *N. Engl. J. Med.* 302(19):1058, 1980.
 469. Rossiter, E., "Technologies for Blood Collection," contract No. 433-4500.0, submitted to the Office of Technology Assessment, May 31, 1984.
 470. Rossiter, E., President, Regulatory Resources, Inc., Richmond, VA, personal communication, June 1984.
 471. Rougeon, F., Kourilsky, P., and Mach, B., "Insertion of a Rabbit **B-globin** Gene Sequence Into *E. coli* Plasmid," *Nuc. Acid. Res.* 2:2365-2375, 1975.
 472. Ruoff, S., Supervisor, Component Laboratories, Blood Services Division, Los Angeles Region American Red Cross, personal communication, Feb. 23, 1984.
 473. Russell, P. S., and Cosini, A. B., "Transplantation," *N. Engl. J. Med.* 301(9):470-79, 1979.
 474. Sala-Trepat, J. M., Dever, J., Sargent, T. O., et al., "Changes in Expression of Albumin and Alpha-fetoprotein Genes During Rat Liver Development and **Neoplasia**," *Biochem.* 18:2167-2178, 1979.
 475. Salvaggio, J., Arquembourg, P., Bickers, J., and Bice, D., "The Effect of Prolonged **Plasma**pheresis on **Immunoglobulins**, Other Serum Proteins, Delayed Hypersensitivity, and **Phytohemagglutinin**-Induced Lymphocyte Transformation," *Arch. Allergy* 41:883-894, 1971.
 476. Samgadharan, M. G., Popovic, M., Bruch, L., et al., "Antibodies Reactive With Human T-Lymphotropic Retroviruses (**HTLV-III**) in the Serum of Patients With AIDS," *Science* 224:506-508, 1984.
 477. Savitsky, J. P., Doczi, J., Black, J., et al., "A Clinical Safety Trial of **Stroma-Free Hemoglobin**," *Clin. Pharmacol. Ther.* 23:73-80, 1978.
 478. Saxton, P., Cable, R., and Katz, A., "Hemophilia Home Care: Distribution of Concentrate to Home Care Patients With Direct Reimbursement by Third Party Payer," presented at the annual meeting of the American Association of Blood Banks, New York, NY, November 1983.
 479. Scannon, F. J., "Molecular Modification of Hemoglobin," *Crit. Care Med.* 10:261-269, 1982.
 480. Scheller, R., Dickerson, R., Boyer, H., et al., "Chemical Synthesis of Restriction Enzyme Recognition Sites Useful for Cloning," *Science* 196:177-180, 1977.
 481. Schiffer, C. A., and Aisner, J., "Platelet and Granulocyte Transfusion Therapy for Patients With Cancer," *Clinical Practice of Blood Transfusion*, L. D. Petz and S. N. Swisher (eds.) (New York: Churchill Livingstone, 1981).
 482. Schiffer, C. A., Aisner, J., Daly, P. A., et al., "Alloimmunization Following Prophylactic Granulocyte Transfusion," *Blood* 54:766-774, 1979.
 483. Schiffer, C. A., and Slichter, S. J., "Platelet Transfusions From Single Donors," *N. Engl. J. Med.* 307(4):245-248, 1982.
 484. Schmeck, H. M., Jr., "Substance Vital to Clot Blood Created in Lab," *New York Times*, Apr. 26, 1984, p. A-1.
 485. Schmidt, P. J., "National Blood Policy, 1977: A Study in the Politics of Health," *Progress in Hematology*, vol. 10, E. B. Brown (cd.) (New York: Grune & Stratton, Inc., 1977), pp. 151-172.
 486. Schmitt, V. W., Associate Director, Plasma Products Management, Blood Services, American Red Cross, Washington, DC, personal communication, Dec. 12, 1983.
 487. Schoeppner, S. L., Ennis, K., and Mallory, D., "Evaluation of Routine ABO and Rh Typing by Microplates in Regional Blood Centers," abstract of poster presentations, **MAABB/PABB** Joint Meeting, Baltimore, MD, Mar. 1-3, 1984.
 488. Schupbach, J., et al., "Serological Analysis of a Subgroup of Human T-Lymphotropic **Retroviruses (HTLV-III)** Associated With AIDS," *Science* 224:503-505, 1984.
 489. Schwartz, S., "Elicitation of Moral Obligation and Self-Sacrificing Behavior," *J. Personality and Soc. Psych.* 15:283-93, 1970.
 490. Sehgal, L. R., Rosen, A. L., Noud, G., et al., "Large-Volume Preparation of Pyridoxylated

- Hemoglobin With High P_{50} ," *J. Surg. Res.* 30: 14-20, 1981.
491. Sell, K. W., statement before Subcommittee on Investigations and Oversight, House Committee on Science and Technology, U.S. Congress, Apr. 13, 14, and 27, 1983.
 492. Sellards, A. W., and Minot, G. R., "The Injection of Hemoglobin in Man and Its Relation to Blood Destruction With Special Reference to the Anemias," *J. Med. Res.* 34:469-494, 1916.
 493. Seto, B., Coleman, W., Jr., Iwarsen, S., and Gerety, R., "Detection of Reverse Transcriptase Activity in Association With the Non-A, Non-B Hepatitis Agent(s)," *Lancet* ii(8409):941-945, 1984.
 494. Sgouris, J. T., and Rene, A. (eds.), *Proceedings of the Workshop on Albumin February 12-13, 1975, Bethesda*, MD, DHEW publication No. (NIH) 76-925 (Washington, DC, U. S. Government Printing Office, 1975).
 495. Sharom, F. J. D., Bonratt, D. G., and Grant, C. W. M. "Glyophorin and the Concanavalin A Receptor of Human Erythrocytes: Their Receptor Function in Lipid Bilayers," *Proc. Natl. Acad. Sci.* 74:2751-2755, 1977.
 496. Sherman, L., "New Plasma Components," Clinics in *Hematology*, W. Bayer (ed.), in press (1984).
 497. Sherman, L. A., "Fresh Frozen Plasma, Cryoprecipitate, Factor Concentrates," *American College of Surgeons 69th Annual Clinical Congress October 16-21, 1983, Postgraduate Course 1: Pre- and Postoperative Care: Blood and How to Use It*, G. S. Moss, Chair, American College of Surgeons, Chicago, IL, 1983.
 498. Shinowara, G. Y., "Enzyme Studies on Human Blood. XI: The Isolation and Characterization of Thromboplastic Cell and Plasma Components," *J. Lab. Clin. Med.* 38:11-22, 1951.
 499. Sic, P., Gillois, M., Boneu, B., et al. "Reconstitution of Liposomes Bearing Platelet Receptors for Human von Willebrand Factor," *Biochem. Biophys. Res. Comm.* 97:133-138, 1980.
 500. Simon, E. R., "Whole Blood vs Red Blood Cells vs No Blood!" *Boswell Hospital Proceedings* 9:10-14, 1983.
 501. Slichter, S. J., "Efficacy of Platelets Collected by Semi-Continuous Flow Centrifugation (Hae-monetics model 30)," *Br. J. Haematology* 38: 131-140, 1978,
 502. Slovitar, H. A., Yamada, H., and Ogashi, S., "Some Effects of Intravenously Administered Fluorochemicals in Animals," *Fed. Proc.* 29: 1755-1757, 1970.
 503. Sloviter, M. A., "Perfluoro Compounds as Artificial Erythrocytes," *Fed. Proc.* 34:1484-1487, 1975.
 504. Smith, P., and Levine, P., "The Benefits of Comprehensive Care of Hemophilia: A Five-Year Study of Outcomes," *Am. J. Pub. Health* 74: 616-617, June 1984.
 505. Snyder, E. L., Associate Professor of Laboratory Medicine, Yale University, personal communication, Feb. 6, 1984.
 506. Solomon, J., "A Federal View: An Examination of Five Years of FDA Licensure of Source Plasma Manufacturers," *Plasma Forum, February 26-27, 1979: A Public Exchange of Views Regarding Plasmapheresis*, W. L. Warner (ed.) (Annapolis, MD: American Blood Resources Association, 1979).
 507. Solomon, J., Clinical Center Blood Bank, National Institutes of Health, personal communication, March 1984.
 - 508a. Solomon, J., "Contribution of the National Institutes of Health to Research on Acquired Immunodeficiency Syndrome (AIDS)," National Institutes of Health, Clinical Center Blood Bank Department, 1984.
 - 508b. Solomon, J., "Legislation and Regulations in Blood Banking," *Federal Legislation and the Clinical Laboratory*, M. Schaeffer (ed.) (Boston: G. K. Hall Medical Publishers, 1981).
 509. Solomon, J., "Regionalization of Blood Services in the Washington, D.C. Area," case study prepared for the Office of Technology Assessment, Washington, DC, March 1984.
 510. Spector, J. I., and Crosby, W. H., "Coagulation Studies During Experimental Hemoglobinemia in Humans," *J. Appl. Physiol.* 38(2): 195, 1975.
 511. Spohn, R. B., *Director of the Department of Consumer Affairs for the State of California v. Irwin Memorial Blood Bank of the San Francisco Medical Society*, Deposition of Bemice M. Hemphill, June 7, 1978.
 512. Stackhouse, R., Chandra, T., Robson, K. J. H., et al., "Purification of Antithrombin III mRNA and Cloning of Its cDNA," *J. Biol. Chem.* 258: 703-706, 1982.
 513. Stanier, R. Y., Duodoroff, M., and Adelberg, E. A., *The Microbial World*, 3rd ed. (Englewood Cliffs, NJ: Prentice-Hall, Inc., 1970).
 514. Steger, L. D., and Desnick, R. J., "Enzyme Therapy. VI: Comparative in Vivo Fates and Effects on Liposomal Integrity of Enzyme Entrapped in Negatively and Positively Charged Liposomes," *Biochem. Biophys. Acta.* 464:530-546, 1977.
 515. Steinitz, M., and Klein, E., "Human Mono-

- clonal Antibodies Produced by Immortalization With Epstein-Barr Virus," *Immunol. Today* 13:38-39, 1981.
- 516a. Stel, H. V., Veerman, E. C. I., and van der Kwast, T., "Detection of Factor VIII/Coagulant Antigen in Human Liver Tissue," *Nature* 303: 530-532, 1983.
 - 516b. Suggs, S. V., Wallace, R. B., Hirose, T., et al., "Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human B₂-microglobulin," *Proc. Natl. Acad. Sci.*, 78:6613-6617, 1981.
 517. Surgenor, D. M., President, Center for Blood Research, Boston, MA, personal communication, December 1983.
 518. Surgenor, D. M., and Schnitzer, S. S., American Blood Commission, "The Nation's Blood Resource 1979 and 1980: A Summary Report," unpublished, 1983.
 519. Sutcliffe, J. G., "Complete Nucleotide Sequence of the *Escherichia coli* Plasmid pBR322," *Cold Spring Symp. Quant. Bio.* 43:77-90, 1980.
 520. Swisher, S. N., and Petz, L. D., "An Overview of Blood Transfusion," *Clinical Practice of Blood Transfusion*, L. D. Petz and S. N. Swisher (eds.) (New York: Churchill Livingstone, 1981).
 521. Switalski, R. W., "American Society of Anesthesiologists Blood Transfusion Practices Survey, 1981, Preliminary Survey Results," Arlington, VA, American Blood Commission National Blood Data Center, unpublished, no date.
 522. Szoka, F. C., and Papahadjopoulos, D., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)," *Ann. Rev. Biochem. Biol.* 9:467-543, 1980.
 523. Tait, R. C., and Boyer, H. L., "On the Nature of Tetracycline Resistance Controlled by the Plasmid pSC 101," *Cell* 13:73-77, 1978.
 524. Tall, A. R., and Green, P. H., "Incorporation of Phosphatidylcholine Into Spherical and Discarded Lipoproteins During Incubation of Egg Phosphatidylcholine Vesicles With High Density Lipoproteins or With Plasma," *J. Biol. Chem.* 256:2035-2044, 1981.
 525. Tarn, S. C., Blumenstein, J., and Wong, J. T., "Soluble Dextran-Hemoglobin Complex as a Potential Blood Substitute," *Proc. Natl. Acad. Sci.*, 73:2128-2138, 1976.
 526. Tarn, S. C., Blumenstein, J., and Wong, J. T., "Blood Replacement in Dogs by Dextran-Hemoglobin," *Can. J. Biochem.* 56:981-984, 1978.
 527. Teague, W. T., Executive Director, Gulf Coast Regional Blood Center, Houston, TX, personal communication, March 1984.
 528. Temin, H. M., and Mizutani, S., "Viral RNA-Dependent DNA Polymerase," *Nature* 226: 1211-1213, 1970.
 529. Thomas, W., International Patent Application No. WO82/03871 (1983).
 530. Till, J. E., and McCulloch, E. A., "A Direct Measurement of the Radiation Sensitivity of Normal Bone-Marrow Cells," *Radiat. Res.* 14:213-219, 1961.
 531. Tomasulo, P., "Blood Service Delivery in South Florida, 1978-1984," prepared for the Office of Technology Assessment, Washington, DC, April 1984.
 532. Tomasulo, P. A., President, South Florida Blood Service, Miami, FL, personal communication, April 1984.
 533. Tomasulo, P. A., "Platelet Transfusions for Nonmalignant Diseases," L. D. Petz and S. N. Swisher (eds.), *Clinical Practice of Blood Transfusion* (New York: Churchill Livingstone, 1981).
 534. Tomasulo, P., "Regional Blood Center Perspective," paper presented at the Annual Meeting of the American Association of Blood Banks, New York, NY, November 1983.
 535. Toole, J., Genetics Institute, Boston, MA, personal communication, February 1984.
 536. Toole, J., Knopf, J., Wozney, J., et al., "Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor," *Nature* 312 (5992): 342-347, 1984.
 537. Tremper, K. K., Friedman, A. E., Levine, E. M., et al., "The Preoperative Treatment of Severely Anemic Patient With a Perfluorochemical Oxygen-Transport Fluid, Fluosol-DA," *N. Engl. J. Med.* 307:277-283, 1982.
 538. Tunis, J. L., "Albumin: 2. Guidelines for Clinical Use," *J. A.M.A.*, 237:460-463, 1977.
 539. Tunis, J., "Methods of Plasma Collection and Fractionation," contract No. 433-5310.o, submitted to the Office of Technology Assessment, Washington, DC, April 1984.
 540. Tye, R. W., Medina, F., and Bolin, R. B., "Modification of Hemoglobin-Tetrameric Stabilization," *Advances in Blood Substitute Research*, R. B. Bolin, R. P. Geyer, and G. J. Nemo (eds.) (New York: Alan R. Liss, Inc., 1983), pp. 41-50.
 541. Tyrell, D. A., Health, T. D., Coney, C. M., et al., "New Aspects of Liposomes," *Biochem. Biophys. Acta.* 457:295-302, 1976.
 542. Ullrich, A., Shine, J., Chirgwin, J., et al., "Rat

- Insulin Genes: Construction of Plasmids Containing the Coding Sequences, " *Science* 196: 1313-1319, 1977.
543. Urdea, M. S., Merryweather, J. P., Mullenbach, G. T., et al., "Chemical Synthesis of a Gene for Human Epidermal Growth Factor Urogastrone and Its Expression in Yeast, " *Proc.Natl.Acad.Sci.* 80:7461-7465, 1983.
 544. U.S. Congress, Congressional Budget Office, **Changing the Structure of Medicare Benefits: Issues and Options** (Washington, DC: U.S. Government Printing Office, March 1982).
 545. U.S. Congress, Congressional Budget Office, **The Effect of PSROs on Health Care Costs: Current Findings and Future Evaluations** (Washington, DC: U. S. Government Printing Office, June 1979).
 546. U.S. Congress, General Accounting Office, **Actions Needed to Stop Excess Medicare Payments for Blood and Blood Products**, HRD-78-172 (Washington, DC: Feb. 26, 1979).
 547. U.S. Congress, General Accounting Office, **Problems in Carrying Out the National Blood Policy**, GAO/HRD-77-150 (Washington, DC: 1978).
 548. U.S. Congress, Office of Technology Assessment, **Assessing the Efficacy and Safety of Medical Technologies**, OTA-H-75 (Washington, DC: U.S. Government Printing Office, stock # 052-003-00593-0, September 1978).
 549. U.S. Congress, Office of Technology Assessment, **Commercial Biotechnology: An International Analysis**, OTA-BA-281 (Washington, DC: U.S. Government Printing Office, stock # 052-003-00939-1, January 1984).
 550. U.S. Congress, Office of Technology Assessment, **Diagnosis Related Groups (DRGs) and the Medicare Program: Implications for Medical Technology—A Technical Memorandum**, OTA-TM-H-17 (Washington, DC: U.S. Government Printing Office, stock #052-003-00919-6, July 1983).
 551. U.S. Congress, Office of Technology Assessment, "Medical Technology and Diagnosis-Related Groups: Evaluating Medicare's Prospective Payment System, " project proposal, Mar. 8, 1984.
 552. U.S. Congress, Office of Technology Assessment, **The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis**, OTA-HCS-23 (Washington, DC: U.S. Government Printing Office, stock #052-003-00918-8, 1983).
 553. U.S. Congress, Office of Technology Assessment, **Variations in Hospital Length of Stay: Their Relationship to Health Outcomes**, OTA-HCS-24 (Washington, DC: U.S. Government Printing Office, stock #052-003-00922-6 August 1983).
 554. U.S. Department of Health, Education, and Welfare, National Institutes of Health, National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources, **Study to Evaluate the Supply-Demand Relationships for AHF and PTC Through 1980**, DHEW publication No. (NIH) 77-1274, Bethesda, MD, 1977.
 555. U.S. Department of Health, Education, and Welfare, National Institutes of Health, National Heart and Lung Institute, National Blood Resource Program, **Summary Report: NHLI's Blood Resource Studies**, DHEW publication No. (NIH) 73-416, Bethesda, MD, June 30, 1972.
 556. U.S. Department of Health, Education, and Welfare, National Institutes of Health, National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources, **Ten-Year Review and Five Year Plan, Section 5: Blood Resources**, final draft, revised November 1982.
 557. U.S. Department of Health and Human Services; National Heart, Lung, and Blood Institute; **Directory of Federally Supported Research Projects in Lung and Blood Diseases and Blood Resources (FY 79)**, NIH publication No. 81-2183, Bethesda, MD, 1980.
 558. U.S. Department of Health and Human Services; National Heart, Lung, and Blood Institute; **Tenth Report of the Director, National Heart, Lung, and Blood Institute, Volume 4: Blood Diseases and Resources**, NIH publication No. 84-2359, Bethesda, MD, 1984.
 559. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, "Update: Acquired Immunodeficiency Syndrome (AIDS) Among Patients With Hemophilia—United States, " **Morbidity and Mortality Weekly Report** 32(47):613-615, 1983.
 560. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, **FDA Blood Products Advisory Committee Annual Report**, July 13, 1982.
 561. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, FDA Blood Products Advisory Committee Meeting, Summary Minutes, Oct. 6-7, 1983.
 562. U.S. Department of Health and Human Services, Public Health Service, Food and Drug

- Administration, Office of Biologics, *FDA Panel on Review of Blood and Derivatives Final Report*, unpublished, Nov. 15, 1979.
563. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, *Working Relationships Agreement Among the Bureaus of Medical Devices, Radiological Health and Biologics*, April 1982.
 564. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, National Center for Drugs and Biologics, *Memorandum to All FDA Registered Blood Establishments on Approval of Two New Blood Preservative Systems*, Bethesda, MD, Oct. 14, 1983.
 565. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Biologics, *Guidelines for the Collection of Platelets by Mechanical Pheresis*, March 1981.
 566. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Biologics, *Recommendations to Decrease the Risk of Transmitting Acquired Immunodeficiency Syndrome (AIDS) From Blood Donors*, Mar. 24, 1983.
 567. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, "Announcement of Consensus Development Conference on Fresh Frozen Plasma: Indications and Risks," Bethesda, MD, Apr. 17, 1984.
 568. U.S. Department of Health and Human Services, Social Security Administration, Health Care Financing Administration, *Your Medicare Handbook*, Social Security Administration publication No. 05-10050, Baltimore, MD, 1983.
 569. Valenzuela, P. Chiron Corp., Emeryville, CA, personal communication, February 1984.
 570. Vehar, G., Keyt, B., Eaton, D., et al., "Structure of Human Factor VIII," *Nature* 312(5992): 337-342, 1984.
 571. Veltkamp, J. J., "What Is the Prospective Impact of the Recombinant DNA Technique on the Production of Human Plasma Derivatives? What Are the Derivatives Where Donor Plasma Could Be Replaced?" *Vox Sang.* 44:390-395, 1983.
 572. Vercellotti, G. M., Hammerschmidt, D. E., Craddock, P. R., et al., "Activation of Plasma Complement by Perfluorocarbon Artificial Blood: Probable Mechanism of Adverse Pulmonary Reactions in Treated Patients and Rationale for Corticosteroid Prophylaxis," *Blood* 59:1299-1304, 1982.
 573. Villa-Komaroff, L., Efstratiades, A., Broome, S., et al., "A Bacterial Clone Synthesizing Pro-insulin," *Proc. Natl. Acad. Sci.* 75:3727-3731, 1978.
 574. Virmani, R., Warren, D., Rees, R., et al., "Effects of Perfluorochemical on Phagocytic Function on Leukocytes," *Transfusion* 23:512-515, 1983.
 575. Voak, D., and Lenox, E., "Principles of Monoclonal Antibodies in Blood Transfusion Work," *Biotest Bulletin* 4:281-290, 1983.
 576. Wallace, E. L., and Wallace, M. A., American Blood Commission, *Hospital Transfusion Charges and Community Blood Center Costs*, prepared under contract with the Division of Blood Diseases and Resources of the National Heart, Lung, and Blood Institute of the Department of Health and Human Services, unpublished, July 1982.
 577. Wallace, J., *Blood Transfusions for Clinicians* (London: Churchill Livingstone, 1977).
 578. Wallen, P., Ranby, M., and Bergdorf, N., *Progress in Fibrinolysis* 5:16-23, J. R. Davidson, I. M. Nilsson, and B. Astedt (eds.) (New York: Churchill-Livingstone, 1981).
 579. Watson, J. D., Tooze, J., and Kurtz, D. T., *Recombinant DNA: A Short Course* (New York: Scientific American Books, Freeman & Co., 1983).
 580. Weimar, W., Van Seyden, A. J., Stebbe, J., et al., "Specific Lysis of an Iliofemoral Thrombus by Administration of Extrinsic (Tissue-type) Plasminogen Activator," *Lancet* i:1018-1020, 1981.
 581. Weinstock, G. M., Rhys, C., Berman, M. R., et al., "Open Reading Frame Expression Vectors: A General Method for Antigen Production in *E. Coli*, Using Protein Fusions to Beta-galactosidase," *Proc. Natl. Acad. Sci.* 80:4432-4436, 1983.
 582. Wessan, L., "Advances in Recombinant DNA Reach Blood Clotting Market," *Genet. Engineering News* 2(6):22, 1982.
 583. Widmann, F. K. (cd.), *Technical Manual* (Washington, DC: American Association of Blood Banks, 1981).
 584. Wield, D., "Alfa-laval Emerging as a Global Force in Industrial Biotechnology Scale-up," *Genet. Engineering News* 3(3):5, 1983.
 585. Wigler, M., Sweet, R., Sire, G. K., et al., "Transformation of Mammalian Cells With